

1 **Comprehensive interrogation of a *Drosophila* embryonic patterning network reveals the**
2 **impact of chromatin state on tissue-specific burst kinetics and RNA Polymerase II**
3 **promoter-proximal pause release**

4

5

6 **George Hunt¹, Roshan Vaid¹, Sergei Pirogov¹, Alexander Pfab¹, Christoph Ziegenhain²,**
7 **Rickard Sandberg², Johan Reimegård³ and Mattias Mannervik^{1*}**

8

9

10

11 1 Dept. Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm,
12 Sweden

13 2 Dept. Cell and Molecular Biology, Karolinska Institutet, Sweden

14 3 Dept. Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden, Science
15 for Life Laboratory, Uppsala University, Uppsala, Sweden

16

17

18 * Correspondence: mattias.mannervik@su.se

19

20

21

22

23 **Abstract**

24 Formation of tissue-specific transcriptional programs underlies multicellular development, but
25 how the chromatin landscape influences transcription is not fully understood. Here we
26 comprehensively resolve differential transcriptional and chromatin states during *Drosophila*
27 dorsoventral (DV) patterning. We find that RNA Polymerase II pausing is established at DV
28 promoters prior to zygotic genome activation (ZGA), that pausing persists irrespective of cell
29 fate, but that release into productive elongation is tightly regulated and accompanied by tissue-
30 specific P-TEFb recruitment. DV enhancers acquire distinct tissue-specific chromatin states
31 through CBP-mediated histone acetylation that predict the transcriptional output of target
32 genes, whereas promoter states are more tissue invariant. Transcriptome-wide inference of
33 burst kinetics in different cell types revealed that while DV genes are generally characterized
34 by a high burst size, either burst size or frequency can differ between tissues. The data suggest
35 that pausing is established by pioneer transcription factors prior to ZGA and that release from
36 pausing is imparted by enhancer chromatin state to regulate bursting in a tissue-specific manner
37 in the early embryo. Our results uncover how developmental patterning is orchestrated by
38 tissue-specific bursts of transcription from Pol II primed promoters in response to enhancer
39 regulatory cues.

40

41

42 Introduction

43 The ability to dynamically regulate gene expression is integral to developmental processes in
44 multicellular organisms by enabling cells that retain identical DNA sequences to form
45 specialized cell types. Early *Drosophila* embryogenesis involves 13 rapid, synchronous nuclear
46 divisions within a syncytium to give rise to ~6000 nuclei that then cellularize, undergo zygotic
47 genome activation (ZGA), and become specified. Dorsoventral (DV) axis specification of the
48 early *Drosophila* embryo is one of the most well studied gene regulatory networks ^{1,2}. During
49 DV patterning, distinct cell fates form in response to an intranuclear morphogen gradient of the
50 maternally supplied REL-family transcription factor Dorsal (Dl) ³⁻⁵. Differential activation of
51 Toll receptors leads to high nuclear import of Dl in ventral regions, low levels of nuclear Dl in
52 lateral regions and an absence of Dl in dorsal regions ⁶. The Dl gradient forms during nuclear
53 cycles 10-14 and induces distinct complements of zygotic genes in ventral, lateral and dorsal
54 regions of the embryo, leading to cell specification at nuclear cycle 14 and formation of
55 presumptive mesoderm, neurogenic ectoderm and dorsal ectoderm, respectively (Fig. 1A). Dl
56 activates genes such as *twist* (*twi*) in the mesoderm and *intermediate neuroblasts defective* (*ind*)
57 in the neuroectoderm, but can also function as a repressor, which restricts genes such as
58 *decapentaplegic* (*dpp*) to the dorsal ectoderm where Dl is absent from the nuclei (Fig. 1B).

59 An important aspect of transcriptional regulation is how regulatory signals are
60 conveyed from enhancers to elicit a transcriptional response at the promoter. Hi-C, Micro-C
61 and microscopy-based data revealed that there are no differences in the topologically associated
62 domain (TAD) structure or enhancer-promoter (E-P) contact frequencies for DV genes between
63 cells in the embryo where they are expressed or silent ^{7,8}. This suggests that E-P looping is not
64 the step that triggers tissue-specific activation of DV genes. Pausing of transcriptionally
65 engaged RNA Polymerase II (Pol II) 30-60 bp downstream of the transcription start site (TSS)
66 has been identified as an important regulatory checkpoint that allows the release of Pol II in to
67 productive elongation to be tightly controlled ^{9,10}. Pol II pausing is prevalent among
68 developmental genes during *Drosophila* embryogenesis ¹¹, and allows cells in a tissue to
69 synchronously activate gene expression ¹².

70 DV tissue mutant embryos, derived from maternal effect mutations, with either the
71 absence (*gd*⁷, dorsal ectoderm), or uniformly low (*Toll^{rm9/rm10}*, neurogenic ectoderm) and high
72 (*Toll^{10B}*, mesoderm) levels of nuclear Dl (Fig. 1a,b), provided an amenable substrate for ChIP-
73 based approaches to characterise DV enhancers and other important regulatory elements based
74 on the enrichment of histone modifications such as H3K27ac and occupancy of the co-activator

75 CBP^{7,13-17}. Nonetheless, a comprehensive genome-wide assessment of the interplay between
76 transcriptional activity and chromatin state across the DV axis is lacking.

77 In this study, we used the DV patterning model to examine the spatio-temporal interplay
78 between transcription and chromatin state. We performed Precision Run-On Sequencing (PRO-
79 seq) on precisely aged tissue mutant *Drosophila* embryos to measure nascent transcription and
80 Pol II pausing genome-wide, alongside chromatin state data from ATAC-seq, ChIP-seq and
81 CUT&Tag. We further inferred transcriptional burst kinetics from single-cell RNA-seq data.
82 Our findings suggest that enhancers and promoters are initially primed for activation
83 competency across cells that adopt distinct fates, but the spatio-temporally regulated
84 acquisition of distinct patterns of enhancer CBP occupancy and histone acetylation in response
85 to the Dl gradient leads to differential DV gene expression by controlling burst kinetics and the
86 release of paused Pol II into productive elongation.

87

88 **Results**

89

90 **Paused Pol II is established at dorsoventral genes prior to their expression in the early**
91 **embryo**

92 To obtain a precise genome-wide assessment of the activity state of Pol II and spatio-temporal
93 differences in zygotic transcription during DV patterning, we performed PRO-seq on naïve
94 wild-type embryos, 60-80 min after egg laying (AEL), and on DV tissue mutant embryos
95 composed entirely of presumptive dorsal ectoderm (*gd*⁷), neurogenic ectoderm (*Toll*^{rm9/rm10}) or
96 mesoderm (*Toll*^{10B}) at 3 and 5 hours AEL (Fig. 1a-d) ¹⁸. For the naïve stage, we also hand-
97 sorted embryos to ensure that they were not older than nuclear cycle (nc) 9, and used the more
98 sensitive qPRO-seq protocol ¹⁹. We identified differentially expressed genes between the
99 mutant embryos by comparing the number of PRO-seq reads mapping to the gene body
100 (defined as the coding sequence (CDS) of the gene), and observed 195 genes that were up-
101 regulated specifically in one of the mutants (Fig. S1a,b and Table S1). A comparison with
102 previously published DV regulated genes ²⁰ showed a large overlap and expression in the
103 expected tissue (Fig. S1c,d). Gene ontologies for the differentially expressed genes were
104 consistent with their expected functions in epithelial, nervous system and muscle development,
105 respectively (Table S2). Most DV regulated genes were expressed at both 3 and 5 h AEL, but
106 some were specific to the later time point (Fig. S1e, Table S1).

107 Many developmental genes exhibit promoter-proximal paused RNA polymerase II (Pol
108 II) ~30-60 bp downstream of the TSS ²¹. To measure pausing, we calculated the pausing index
109 from the ratio of PRO-seq reads mapping to the promoter (from 50 bp upstream of the TSS to
110 100 bp downstream of the TSS) and the sum of reads mapping to the promoter and the gene
111 body, which revealed that DV genes, as well as anterior-posterior (AP) patterning genes, were
112 more highly paused than non-DV genes expressed in these embryos (Fig. 1e,f, S1f).
113 Interestingly, Pol II pausing was observed at DV genes already in the naïve stage, prior to their
114 expression (Fig. 1d,e).

115 To ensure that detection of paused Pol II in the naïve stage was not due to sample
116 contamination with older embryos, we measured the gene body read counts and pausing index
117 of zygotic genes expressed at specific stages of development ²² (Fig. S1g-j). Genes already
118 expressed at nc 7-9 and nc 9-10 had higher gene body qPRO- and PRO-seq signal than DV
119 genes and genes expressed at the syncytial (nc 11-13) and cellularized (nc 14) blastoderm
120 stages, demonstrating that the experiments captured properly staged embryos (Fig. S1g,h).
121 Whereas DV genes were paused at the naïve stage, genes expressed at the naïve stage had a

122 low pausing index, consistent with previous findings²³ (Fig. S1j). Core promoter motifs have
123 been shown to strongly influence Pol II recruitment and pausing^{9,24,25}. Examination of the
124 CORE database²⁶ and *de novo* motif analysis showed that DV genes were highly enriched for
125 core promoter motifs²⁷, such as Initiator (Inr), downstream promoter element (DPE) and
126 TATA-box, compared to other genes (Fig. S1k-n and Table S3), likely contributing to their
127 high pausing index.

128 High Pol II pausing was maintained at dorsal ectoderm, neuroectoderm, and mesoderm-
129 specific genes across all three DV mutants (Fig. 1f), but gene body reads were elevated in
130 specific mutants, as exemplified by *decapentaplegic* (*dpp*), *intermediate neuroblasts defective*
131 (*ind*) and *twist* (*twi*) (Fig. 1d). Similar results were obtained with Pol II antibodies in CUT&Tag
132 on *Toll* mutant embryos (Fig. S1o). The pausing index for DV genes was lower in the tissue
133 mutant of expression (Fig. 1g). To address whether the reduction in pausing was due to the
134 elevated gene body reads in the tissue of expression, or a decrease in reads for promoter-
135 proximal paused Pol II, we measured the signal for these regions separately for all genes (Fig.
136 S1p, Table S1), and generated metaplots of PRO-seq read density (Fig. 1h). The promoter-
137 proximal Pol II signal was similar among the three mutants for most genes at 3 h (AEL), and
138 the reduced pausing index was mostly explained by the elevation of gene body reads,
139 suggesting a key role for pause release in DV gene transcription. The observation that DV
140 genes become highly paused in naïve embryos prior to their transcription and that pausing is
141 maintained in different tissue contexts, irrespective of transcription, demonstrates that pause
142 release is a major regulatory step in tissue-specific DV transcription.

143

144 **Enhancer chromatin state reflects tissue-specific DV gene transcription**

145 To identify what controls the release of paused Pol II into productive elongation, we examined
146 the chromatin states of enhancers and promoters for DV genes. Occupancy of p300/CBP and
147 enrichment of the p300/CBP catalyzed mark H3K27ac are hallmarks of active enhancers²⁸⁻³¹
148 and DV enhancers have previously been identified based on differential H3K27ac^{7,14}. We
149 screened for DV enhancers by correlating differential expression with genomic regions that
150 exhibit tissue-specific *Drosophila* CBP (Nejire) occupancy, H3K27ac enrichment and
151 chromatin accessibility (ATAC-seq) (Fig. 2a).

152 We assigned genomic regions with differential occupancy and accessibility to target
153 genes within the same topologically associated domain (TAD), and identified 176 putative DV
154 enhancers linked to 107 promoters (Fig. S2a,b and Table S4). Most genes were associated with
155 one or two DV enhancers, suggesting that our approach discerns critical regulatory sequences,

156 but a few genes had multiple enhancers (Fig. S2c). Examining the distribution of enhancer-
157 TSS genomic distances revealed a class of promoter-proximal enhancers, but the majority of
158 enhancers (85%) were distal (> 700 bp) from their targets (Fig. S2d). DV enhancers showed a
159 characteristic pattern of H3K27ac flanking the central maxima of CBP enrichment and region
160 of accessible chromatin (Fig. S2e), likely reflects CBP recruitment by DNA-binding TFs (Fig.
161 S2e,f). We validated our enhancer identification strategy by examining overlapping genomic
162 regions tested in a high-throughput transgenic reporter-gene assay ³², for which we observed
163 enrichment of annotation terms associated with dorsal ectoderm expression for *gd*⁷ enhancers,
164 ventral ectoderm for *Toll*^{rm9/rm10} enhancers and mesoderm for *Toll*^{10B} enhancers (Fig. S2g).
165 Examples of regions overlapping DV enhancers tested in reporter assays that recapitulate the
166 expected spatial expression patterns are shown in Fig. S2h ³². We conclude that chromatin state
167 data is highly efficient in identifying tissue-specific enhancers.

168 We categorized enhancers based on the tissue of expression of their target genes and
169 observed high tissue specificity of elevated chromatin accessibility, CBP occupancy and
170 H3K27ac (Fig. 2b and S2i). Strikingly, a chromatin state enhancer score based on the combined
171 tissue-specific signal for CBP, H3K27ac and ATAC-seq could accurately predict the level of
172 expression as determined by PRO-seq (Fig. 2c, R^2 values 0.78, 0.62, 0.69 for dorsal ectoderm,
173 neuroectoderm and mesoderm enhancers, respectively), and had higher predictive value when
174 combined than individually (Fig. S2j). The chromatin state of DV promoters varied less
175 between tissues and predicted the expression of target genes with less accuracy (Fig. 2d,e, Fig.
176 S2j,k). In summary, the data suggests that whereas enhancer chromatin state reflects tissue-
177 specific expression, the chromatin state at promoters is more tissue-invariant and may allow
178 recruitment and establishment of paused Pol II to prime DV promoters for transcription in all
179 three germ layers.

180

181 **CBP is catalytically active at enhancers but enzymatically inactive at promoters**

182 The observation that occupancy of the CBP coactivator is far less tissue-specific at DV
183 promoters than at enhancers indicates that it may have distinct functional roles at enhancers
184 and promoters. The presence of CBP at promoters does not lead to H3K27ac in tissues where
185 the gene is silent (Fig. 2f,g), indicating that the catalytic activity of CBP is modulated. Since
186 CBP occupancy at DV enhancers correlates with transcription and H3K27ac, the data suggest
187 that enhancer-bound CBP is catalytically active and mediates tissue-specific H3K27ac (e.g.
188 close-up of the *twi* locus in Fig. 2g). Whereas CBP occupancy occurred at focused enhancer
189 and promoter regions, tissue-specific H3K27ac spreads over larger distances covering

190 regulatory and genic regions of DV genes (Fig. 2f and S2f), indicating that transient
191 associations of CBP with larger genomic regions may explain the dispersed H3K27ac pattern.
192 Our data is consistent with a model where promoter-bound CBP supports Pol II recruitment
193 and pausing in an enzymatically-independent manner ³³, whereas catalytic CBP activity at
194 enhancers is critical for tissue-specific histone acetylation and release from pausing.

195 In mammals, non-coding transcription is a predictive marker of active enhancers and
196 enhancer RNAs (eRNAs) can allosterically activate the HAT activity of p300/CBP ³⁴⁻³⁶ and are
197 implicated in supporting the transition of paused Pol II into elongation ³⁷. *Drosophila* eRNA
198 transcription also correlates with enhancer activity ³⁸, but direct comparisons of eRNA levels
199 between the same enhancer in active and inactive cellular contexts are lacking. From the PRO-
200 seq signal at intergenic enhancers and the non-coding strand of genic enhancers, we detected
201 eRNAs that were more abundant in the tissue where the target gene was expressed (Fig. 2h).
202 For example, at the intronic *dpp* E1 enhancer we detected an eRNA with strong antisense
203 transcription specific to *gd*⁷ embryos (Fig. S2l). It is possible that these eRNAs contribute to
204 activating CBP catalytic activity at enhancers ³⁵.

205 *Drosophila* eRNAs are not as abundant as in mammals, but interestingly, Pol II
206 CUT&Tag enrichment at DV enhancers was strong, whereas the PRO-seq signal was low
207 compared to promoters (Fig. 2i). It therefore appears that Pol II is efficiently recruited to both
208 promoters and enhancers, but that Pol II engages in transcription to a lesser extent at enhancers.
209 This suggests that features specific to enhancers and promoters are involved in establishing
210 transcriptionally engaged Pol II at a post-recruitment step.

211 Overall, we show that by integrating genome-wide data providing multiple indicators
212 of chromatin state with transcription, key tissue-specific enhancers can be accurately identified.
213 The data indicate that an active chromatin state is established by tissue-specific recruitment of
214 CBP to enhancers, which leads to histone acetylation across DV gene loci. The finding that the
215 chromatin state of promoter regions is less tissue-specific may reflect the uniform recruitment
216 of paused Pol II across tissues and indicates that tissue-specific signals from the enhancer
217 chromatin state trigger the release of paused Pol II into elongation.

218

219 **Tissue-specific transcription factors are enriched at DV enhancers**

220 To identify transcription factors (TFs) involved in recruiting CBP and H3K27ac to DV genes,
221 we performed a *de novo* motif analysis of DV enhancers using the MEME suite ³⁹. A motif for
222 Mad, the Smad protein that transduces Dpp signalling, was enriched in dorsal ectoderm
223 enhancers, whereas Dl motifs were enriched in neuroectoderm and mesoderm enhancers (Table

224 S5). We then plotted the enrichment of known motifs from the JASPAR database ⁴⁰ at DV
225 enhancers, which revealed that Zelda (Zld) and Brinker (Brk) motifs were the most strongly
226 enriched in dorsal ectoderm enhancers, Snail (Sna) and Dl in neuroectoderm, and Su(H)
227 (Suppressor of Hairless) and Twist (Twi) motifs in mesoderm enhancers (Fig. S3a-b and Table
228 S6). We also examined published ChIP-nexus data for Dl ⁴¹ and ChIP-seq data for several
229 tissue-specific TFs ^{13,14}, which showed that Mad and Zerknüllt (Zen) occupancy is common in
230 dorsal ectoderm enhancers, Dl in neuroectoderm enhancers, whereas Twi binding is enriched
231 in mesoderm enhancers (Fig. S3c). Locus-specific occupancy is also evident in the browser
232 snapshots of *dpp*, *ind* and *twi* (Fig. 2f). Together, these analyses show that tissue-specific
233 transcriptional activators (e.g. Mad, Zen, Twi) and repressors (Brk and Sna) have motifs in and
234 bind to the identified DV enhancers. They may contribute to differential CBP and H3K27ac
235 recruitment, but must act after or in parallel to Dl, since the genes encoding these TFs are
236 themselves targets of the Dl gradient.

237

238 **DV transcription occurs within the context of a tissue-invariant chromatin conformation**

239 Early *Drosophila* embryogenesis involves the rapid formation of an elaborate 3D chromatin
240 organization characterized by the establishment of TADs and the formation of enhancer-
241 promoter loops ^{42,43}. Although TAD formation coincides with ZGA, it occurs independently of
242 transcription, is tissue invariant and gene expression is largely unaltered by major disruptions
243 of chromosome topology ^{7,42,44}. Enhancer-promoter loops are also maintained across tissues in
244 the early embryo ^{7,8,42,43,45}, so although these loops are important for positioning enhancers and
245 promoters in proximity to each other, additional regulatory components are required to drive
246 tissue-specific expression. Consistently, despite the major differences in chromatin state and
247 transcription, the genome organization of the DV-regulated genes *dpp*, *ind* and *twi* appear
248 largely tissue invariant between *Toll* mutants (Fig. S3d) ⁷.

249

250 **Tissue-specific P-TEFb recruitment releases Pol II into productive elongation at DV 251 genes**

252 Since both chromatin conformation as well as the chromatin state at promoters is largely tissue
253 invariant and may reflect the uniform recruitment of paused Pol II across tissues, signals from
254 the enhancer chromatin state may trigger the release of paused Pol II into elongation. A critical
255 step in the release of paused Pol II is the phosphorylation of negative elongation factors and
256 the Pol II C-terminal domain (CTD) by the P-TEFb kinase, consisting of CDK9 and Cyclin T
257 (CycT) (Fig. 3a) ^{46,47}. To investigate if tissue-specific activity of P-TEFb at DV genes is

regulated by differential recruitment or enzymatic activation, we performed CycT and CDK9 CUT&Tag in 2-4 h *Toll* mutant embryos. This revealed that P-TEFb occupancy is more strongly associated with dorsal ectoderm promoters in *gd⁷* embryos, neuroectoderm promoters in *Toll^{rm9/rm10}* embryos, and mesoderm promoters in *Toll^{10B}* embryos (Fig. 3b and S4a). We validated this result by ChIP-qPCR, showing tissue-specific CycT enrichment at DV promoters (Fig. S4b). Interestingly, we observed comparable levels of enrichment, and even higher tissue-specificity at DV enhancers (Fig. 3b,c and S4c). This suggests that enhancer-binding factors load the P-TEFb complex and direct it to the corresponding promoter. To test this, we investigated P-TEFb occupancy at the *Dorsocross (Doc)* locus that consists of three genes (*Doc1*, *Doc2* and *Doc3*) and five enhancers (Fig. 3d). CycT was highly enriched at both enhancers and promoters in the dorsal ectoderm (*gd⁷* embryos) compared to the other tissue-types. We then examined CycT occupancy in embryos homozygous for a deletion of the *Doc* E1 enhancer⁸. Removal of this single enhancer marginally reduced expression of the *Doc* genes and had minimal effects on the chromatin state of the locus (Fig. S4d,e), reflecting functional redundancy with the intact enhancers that maintain promoter contacts⁸. Nevertheless, by ChIP-qPCR we could detect a reduction in the occupancy of CycT at the *Doc* promoters in embryos lacking the E1 enhancer (Fig. 3e), indicating that enhancers modulate loading of P-TEFb to promoters.

One factor that has been implicated in P-TEFb recruitment is the tandem bromo- and extra-terminal domain (BET) protein BRD4, known as female sterile (1) homeotic (fs(1)h) in *Drosophila*^{48,49}. We performed BRD4/fs(1)h CUT&Tag and found that it is also more strongly associated with DV promoters and enhancers in the tissue of target gene expression (Fig. 3b-d, S4a and c), and that occupancy at the *Doc* promoters was reduced in the absence of the E1 enhancer (Fig. 3e). Although BRD4/fs(1)h can recognize acetylated histones through its bromodomains, occupancy was restricted to enhancers and promoters and did not overlap the more distributed H3K27ac pattern (Fig. 3c and S4a). This indicates that other histone modifications or factors binding accessible chromatin at enhancers may be more important for BRD4/fs(1)h recruitment than H3K27ac.

Tissue-specific enrichment of P-TEFb suggests that this kinase could be limiting for transcription in non-expressing tissues. We therefore over-expressed Cdk9 and CycT in early embryos with the maternal tub-Gal4 driver, leading to more than 10-fold increased expression in embryos (Fig. 3f). Although occupancy of P-TEFb did not increase at tested promoters according to CycT ChIP-qPCR (Fig. S4f), expression of DV genes was elevated (Fig. 3f). Interestingly, the number of embryos with DV expression detected outside the normal

292 expression domain was significantly increased by P-TEFb over-expression for all DV genes
293 examined by whole-mount *in situ* hybridization (Fig. 3g and S4g). Ectopic expression may
294 result from titration of negative regulators of P-TEFb, such as the 7SK snRNP that sequesters
295 and inactivates the kinase ⁵⁰, since promoter occupancy did not change upon P-TEFb
296 overexpression. Consistent with this notion, the frequency of ectopic expression correlated with
297 the level of CycT at gene promoters in non-expressing tissues ($R = 0.72$, Fig. S4h).

298 Together, the results suggest that both regulated recruitment of P-TEFb as well as relief
299 from inhibition may be important for tissue-specific release of Pol II from promoter-proximal
300 pausing. Our data show that BRD4/fs(1)h and P-TEFb are enriched in the tissue where the
301 genes are expressed and suggest that differential recruitment of these factors leads to pause
302 release, but indicate that activation of P-TEFb kinase activity is also necessary.

303

304 **Repressors block the release of paused Pol II into elongation and exclude H3K27ac or
305 induce Polycomb-mediated H3K27me3**

306 To decipher if tissue-specific control of Pol II pausing requires active repression in non-
307 expressing cells, we compared the chromatin state at genes regulated by the Dl and Snail
308 repressors (Fig. 4a). Dl is converted to a repressor when its binding sites are flanked by AT-
309 rich elements that recruit Capicua (Cic) and the co-repressor Groucho, resulting in long-range
310 repression to delimit the ventral boundary of dorsal ectoderm specific genes ^{51,52}. In the
311 mesoderm, Snail (Sna) works as a short-range repressor by recruiting the CtBP and Ebi co-
312 repressors to shut down neuroectoderm-specific enhancers ^{15,53,54}. Publicly available Dl ChIP-
313 nexus ⁴¹ and Sna ChIP-seq ^{13,14} data identified peaks in 5-33% of DV enhancers (Fig. S5a),
314 allowing us to identify 13 putative Sna-target genes and 6 Dl-target genes (Fig. 4).

315 We found that the Sna repressor did not prevent occupancy of the Dl activator or induce
316 chromatin compaction in the mesoderm (Fig. S5b,c). Instead, prevention of H3K27ac at DV
317 loci appears to be a major target of Sna-mediated repression (Figs. 2b, 4b,c). This suggests that
318 Sna quenches the Dl activator in the mesoderm by preventing CBP-mediated H3K27ac. By
319 contrast, when Dl acts as a repressor, it does not block H3K27ac at its targets in the
320 neuroectoderm, although these genes are hypoacetylated in the mesoderm (Fig. 4d). Instead,
321 the Polycomb-catalyzed mark H3K27me3 accumulates at Dl-repressed targets in both the
322 neuroectoderm and mesoderm (Fig. 4d), indicating that Polycomb silencing is an important
323 enforcer of Dl-mediated repression. However, Sna-targets did not accumulate H3K27me3 in
324 the mesoderm (Fig. 4c), consistent with the notion that Sna represses transcription by a different
325 mechanism.

326 H3K27me3, which anti-correlates with DV gene activation ¹³, accumulates across
327 genomic regions that encompass the gene bodies of DV genes in a tissue-specific manner (Fig.
328 4e, f). However, Polycomb group proteins (PcGs) have been shown to interfere with Pol II
329 initiation and elongation checkpoints ⁵⁵⁻⁵⁷. ChIP-seq data for the Polycomb Repressive
330 Complex 1 (PRC1) component Polycomb (Pc) in 2-4 h AEL wildtype embryos ^{13,14} detected
331 Pc enrichment specifically at DV promoters and not at enhancers (Fig. S5d,e). We found that
332 39% of the DV promoters, but only 4% of enhancers, overlapped known *Drosophila* Polycomb
333 Response Elements (PREs) (Fig. S5f) ⁵⁸. The strong promoter bias of Pc occupancy suggests
334 that silencing may also involve impeding Pol II activity post-recruitment at promoters.
335 Consistent with this is the retention of similar levels of paused Pol II at DV promoters across
336 tissues, suggesting that DV repressors inhibit the release of paused Pol II ⁵⁹. Together, our data
337 show that whereas Dl-mediated repression is accompanied by PcG silencing and H3K27me3,
338 repression by Sna involves prevention of H3K27ac without induction of H3K27me3, but both
339 mechanisms impair the release of paused Pol II into elongation.

340

341 **DV enhancers and promoters are temporally primed by pioneer factors for increased
342 accessibility prior to induction of DV transcription**

343 We next aimed to complement our tissue-resolved map of the activity of DV enhancers and
344 promoters by temporally resolving chromatin and transcriptional state dynamics during DV
345 patterning (Fig. 5a). We plotted the temporal dynamics of chromatin accessibility at DV
346 enhancers and promoters using ATAC-seq data from wild-type embryos through nuclear cycles
347 11-13, immediately preceding ZGA ⁶⁰. Since the Dl gradient response gradually appears
348 between nuclear cycles (nc) 12-14, we expect chromatin accessibility to be largely uniform
349 across cells in wild-type embryos during nc 11-13. We found that both DV enhancers and
350 promoters are more accessible than shuffled sites representative of the genomic background
351 prior to the initiation of DV gene transcription (Fig. 5b).

352 Consistent with the early priming of DV regulatory elements, the pioneer factor Zld,
353 which has been shown to potentiate Dl activity at DV enhancers ⁶¹, is highly enriched at DV
354 enhancers and promoters already in nc 8 embryos (Fig. S6a,b) ⁶². Alongside Zld, three factors
355 with pioneer-like activities in the early embryo have been identified, Odd-paired (Opa) ⁶³,
356 CLAMP ⁶⁴ and GAGA-factor (GAF, also known as Trithorax-like, Trl) ⁶⁵. We found that Opa
357 and CLAMP occupy both DV enhancers and promoters, whereas GAF favours DV promoters
358 (Fig. S6c). We analyzed published ATAC-seq data from embryos where each pioneer factor
359 had been perturbed individually (Fig. 5c). We observed a small loss of accessibility at DV

360 promoters upon *GAF* inactivation, an unexpected slight increase in enhancer accessibility in
361 *CLAMP* RNAi embryos, virtually no effect of *opa* RNAi, and a more pronounced loss at both
362 DV enhancers and promoters in *zld* RNAi embryos⁶³⁻⁶⁵ (Fig. 5c). This is consistent with earlier
363 work demonstrating a function for Zld in expression and accessibility of DV genes^{61,62}.

364

365 **Temporal changes to enhancer accessibility correlate with variations in DV expression**

366 To explore spatio-temporal accessibility dynamics during the induction of DV responsive
367 transcription, we analyzed our *Toll* mutant ATAC-seq data from three time points covering
368 early, intermediate and late phases of ZGA (3 h, 4 h and 5 h AEL, respectively) (Fig. 5a).
369 ATAC-seq revealed that tissue-specific differences in the accessibility of DV enhancers were
370 augmented from 3 h to 5 h (Fig. 5d). DV promoters, although less tissue-specific in
371 accessibility, also gained accessibility over time across tissues (Fig. 5d). We quantified changes
372 in accessibility across the time course for DV enhancers specifically in the tissue of target gene
373 activity, to identify enhancers that gained (\log_2 fold change ≥ 0.5), lost (\log_2 fold change ≤ -0.5) or
374 retained stable accessibility (Fig. 5e). While the majority of enhancers gained
375 accessibility or remained stably open over time in the tissue of expression, some lost
376 accessibility (Fig. 5e,f). Measuring the PRO-seq gene body expression at early (2.5- 3 h) and
377 late (4.5-5 h) phases of DV-responsive transcription revealed corresponding effects on
378 transcription (Fig. 5g).

379 The closing down of specific enhancers may indicate transfers of regulatory control
380 between enhancers that drive different spatio-temporal expression patterns of the same gene.
381 The locus encoding the dorsal ectoderm-expressed gene *schnurri* (*shn*) exemplifies how
382 chromatin accessibility changes at enhancers can correspond to their spatio-temporal activities,
383 while promoter accessibility can be maintained or gained across tissues (Fig. S6d-f). The *shn*
384 E1 enhancer is primed by chromatin accessibility through nc 11-13, and as a result has
385 accessibility in all the tissue mutants at the start of nc 14 (3 h) (Fig. S6e,f). The E1 enhancer
386 closes down in *Toll^{rm9/rm10}* and *Toll^{10B}* embryos at 4 h, and in *gd⁷* embryos at 5 h.
387 Decommissioning of E1 occurs concomitantly with a gain in accessibility for the upstream E2
388 enhancer specifically in *gd⁷* embryos from 4 h onwards, suggesting regulatory control of *shn*
389 is transferred from E1 to E2 as development proceeds (Fig. S6e,f). In contrast, accessibility at
390 the *shn* promoter increases from 3 h to 5 h in a largely tissue invariant manner. In support of
391 E1 and E2 driving early and late *shn* expression, reporter gene activities driven by fragments
392 overlapping E1 and E2 have distinct spatial and temporal patterns that recapitulate the early
393 and later embryonic expression patterns of *shn*, respectively (Fig. S6f)³².

394 The data suggest that DV enhancers become accessible prior to DV gene transcription
395 with the help of Zelda, and that dynamic alterations in accessibility correlate with spatial and
396 temporal changes in transcription. By contrast, DV promoters maintain more stable
397 accessibility across tissues consistent with the retention of paused Pol II.

398

399 **CBP-mediated acetylation primes a subset of DV enhancers for rapid induction of tissue-
400 specific transcription**

401 To investigate if the temporal priming of chromatin accessibility at DV enhancers and
402 promoters is accompanied by changes in histone modifications, we examined spike-in
403 normalized ChIP-seq data for a wide range of histone marks from nc 8, 12, 14a (early) and 14c
404 (late) wild-type embryos (Fig. 5h and Fig. S6g) ⁶⁶. This showed that the CBP-catalyzed marks
405 H3K27ac, H3K18ac and H4K8ac gradually accumulated at enhancers and promoters, with
406 enrichment elevated relative to shuffled regions already by nc 8 (Fig. S6g). By contrast,
407 deposition of non-CBP catalyzed H3K9ac, and methylation of H3K4 (H3K4me1/me3)
408 occurred co-transcriptionally at nc 14 (Fig. 5h and Fig. S6g). Interestingly, a greater proportion
409 of DV enhancers than non-DV enhancers were marked with H3K27ac, H3K18ac and H4K8ac
410 prior to ZGA, but by nc 14 the overlap was similar between DV and non-DV enhancers (Fig.
411 5h). We determined the overlap of the enhancers with acetylation over time (Fig. S6h), and
412 identified 48 DV enhancers with any CBP catalyzed acetylation already present at nc 8 (Fig.
413 5i). Of these, 96% overlap Zld ChIP-seq peaks from the same stage, compared to 46% of the
414 non-acetylated DV enhancers (Fig. S6i) ⁶⁶.

415 The deposition of histone acetylation at a subset of DV enhancers prior to ZGA suggests
416 that CBP is recruited to chromatin before DV transcription commences. To test this, we
417 performed CUT&Tag on hand-sorted nc 7-9, 11-13, and 14 embryos, which demonstrated that
418 CBP was enriched at DV enhancers and promoters relative to shuffled genomic regions already
419 at nc 7-9 (Fig. S6j). The Zld-bound early acetylated DV enhancers were more enriched for CBP
420 and had markedly higher accessibility than non-acetylated enhancers across the pre-ZGA
421 nuclear cycles (Fig. 5j).

422 To assess whether the early establishment of an active chromatin state at a subset of
423 DV enhancers influenced target genes, we examined the chromatin state at DV promoters.
424 Promoters linked to the early acetylated enhancers were also more enriched for histone
425 acetylation than promoters linked to non-acetylated enhancers, were more accessible, and had
426 stronger CBP enrichment (Fig. S6k,l). To see whether the early established active chromatin
427 states influenced DV transcription, we plotted the PRO-seq gene body expression for target

428 genes from the tissue mutant of expression at early (2.5- 3 h) and late (4.5-5 h) stages (Fig. 5k).
429 PRO-seq revealed that DV genes with early established active enhancer and promoter
430 chromatin states established stronger tissue-specific transcription at the beginning of nc 14
431 (2.5-3 h AEL). Thus, our data suggest that a subset of DV enhancers are primed by Zld for
432 rapid establishment of an active chromatin state defined by elevated chromatin accessibility,
433 recruitment of CBP and enrichment of CBP-catalyzed histone acetylations, and that this results
434 in rapid induction of tissue-specific transcription.

435

436 **Strong P-TEFb enrichment at DV promoters is not observed until gene expression is
437 initiated**

438 Since DV genes are paused but not expressed in naïve embryos, we examined when P-TEFb
439 and BRD4/fs(1)h became associated with these genes. We performed CUT&Tag for CDK9
440 and BRD4/fs(1)h on nc 7-9, 11-13 and 14 embryos. We detected significant enrichment of
441 BRD4/fs(1)h at DV enhancers and promoters, relative to shuffled genomic regions, already at
442 nc 7-9 (Fig. S6j). The promoters of DV genes with early established enhancer and promoter
443 chromatin states and stronger initiation of tissue-specific transcription at nc 14 also had
444 stronger enrichment of BRD4/fs(1)h than other DV promoters across the time course (Fig. 5l).
445 Interestingly, although weak enrichment of CDK9 was observed at nc 7-9 and 11-13 at DV
446 promoters linked to both early acetylated and not-acetylated enhancers, strong CDK9
447 recruitment occurred concomitantly with the induction of expression at nc 14, with promoters
448 linked to early acetylated enhancers having the strongest occupancy (Fig. 5l).

449 Taken together, the data suggest that DV enhancers are temporally primed by the
450 pioneer factor Zld leading to an active chromatin state and BRD4/fs(1)h recruitment prior to
451 the induction of DV-responsive transcription. However, strong loading of P-TEFb to the
452 promoter does not occur until nc 14, which may be the trigger for the rapid release of paused
453 Pol II and induction of tissue-specific gene expression.

454

455 **Identification of DV cell clusters from single-cell expression data**

456 Quantitative studies have revealed that transcription is stochastic and occurs in bursts⁶⁷. Our
457 results show that the DV genes are regulated by pause release, but mediation of the release of
458 paused Pol II to produce bursts of transcription is poorly understood. We analyzed single-cell
459 RNA-seq (scRNA-seq) data from wild-type and *Toll* mutant 2.5-3.5 h (AEL) embryos⁷ to link
460 these processes. Clustering of single-cell expression profiles previously identified 15 clusters
461 representing different cell identities in the early embryo (Fig. S7a)⁷. We performed principal

462 component analysis (PCA) using the DV genes identified by PRO-seq on cells from the
463 ectoderm, neural and mesoderm clusters, and used shared nearest neighbor (SNN) clustering
464 on the first 10 principal components to assign 6 new clusters and visualized it with Uniform
465 Manifold Approximation and Projection (UMAP) (Fig. 6a). Mapping the expression of dorsal
466 ectoderm-, neuroectoderm- and mesoderm-specific genes in these cells showed that they
467 distinguish different clusters of cells on the UMAP (Fig. S7b). The expression of marker genes
468 was used to identify clusters as dorsal ectoderm (*dpp*, *Doc1*, *ush*), neuroectoderm (*ind*, *sog*,
469 *brk*), older neural cells (*scrt*, *ase*, *nerfin-1*), mesoderm (*twi*, *sna*), older mesoderm or myoblasts
470 (*Mef2*, *meso18E*, *sns*, *sing*) and a common cell cluster (Figs. 6a and S7c, Table S7). UMAPs
471 from *gd*⁷, *Toll*^{rm9/rm10} and *Toll*^{10B} embryos revealed the absence of specific clusters in mutant
472 embryos (Fig. 6a). Mesoderm cells were almost completely absent in *gd*⁷ and *Toll*^{rm9/rm10}
473 embryos, and dorsal ectoderm cells were mostly depleted from *Toll*^{rm9/rm10} and *Toll*^{10B} embryos,
474 whereas neuroectoderm cells were largely missing from *gd*⁷ but only moderately reduced in
475 *Toll*^{10B} embryos (Fig. 6a and S7d). This shows that the mutant embryos largely reflect the three
476 presumptive germ layers, but that *Toll*^{10B} embryos consist of 49% mesoderm cells and 34%
477 cells that resemble neuroectoderm (Fig. S7d). The scRNA-seq profiles of *dpp*, *ind* and *twi* in
478 *Toll* mutant embryos are shown in Fig. S7e.

479

480 **Transcriptome-wide inference of burst kinetics in different cell types reveals that DV 481 genes have high burst size capacities and constrained burst frequencies**

482 The scRNA-seq data from wild-type embryos was used to infer transcriptional burst kinetics
483 based on a two-state model of transcription ⁶⁸ (Fig 6b). The two-state model consists of four
484 parameters that may accommodate different transcriptional kinetics. The rate of transition to
485 the active state, k_{on} ; the rate of transition to the inactive state, k_{off} ; the rate of transcription in
486 the active state, k_{syn} ; and the mRNA degradation rate, k_{deg} . Here, we mainly characterized
487 bursting by the burst frequency (k_{on} ; in units of mean mRNA degradation rate) and burst size
488 (mean number of transcripts produced per active burst; k_{syn}/k_{off}). We modelled gene expression
489 using bootstrapped maximum likelihood inferences to obtain estimates and confidence
490 intervals on burst frequency and size ⁶⁸, and removed genes with no or low burst size (non-
491 expressed) and uncertain kinetic parameters. Burst kinetics were determined for a total of 2232
492 genes, including 125 DV genes, in cells of the dorsal ectoderm, neuroectoderm and mesoderm
493 clusters (Table S8), and the kinetic values inferred were highly concordant between two
494 different wild-type lines (*w¹¹¹⁸* and *PCNA:eGFP*, Fig. S8a). The analysis revealed that DV
495 genes have high burst sizes and low burst frequencies compared to non-DV genes, suggesting

496 that they fire infrequently but produce many transcripts per burst (Fig 6c and S8b). Since high
497 burst size has previously been associated with the occurrence of certain core promoter motifs
498⁶⁸, we plotted the burst sizes and frequencies of genes associated with no motifs, with individual
499 motifs or with a combination of promoter motifs (Fig. 6d). This showed that genes associated
500 with Inr, DPE and TATA had a high burst size but low burst frequency. Since these motifs are
501 overrepresented in the DV genes (Fig. S1j-m), it may partly explain their high burst size
502 capacity. We also plotted the burst size and frequency relative to the level of Pol II promoter-
503 proximal pausing genome-wide (Fig. 6e). We noted a correlation between pausing and burst
504 size, but not burst frequency. Pausing correlated better with burst size than burst frequency also
505 for DV genes but the correlation was weaker, likely due to the small sample size (Fig. S8c).
506 Thus, an enrichment of core promoter motifs and high pausing may explain the high burst size
507 of DV genes.

508 By comparing the burst kinetics inferred in the dorsal ectoderm, neuroectoderm (early)
509 and mesoderm (early) cell clusters, we were able to measure changes in DV gene burst sizes
510 and frequencies between cells where these genes are active or inactive (Fig. 6c). Comparison
511 between the clusters showed that both burst size and burst frequency were significantly higher
512 for DV genes in the cluster of expression (Fig. 6c). To explore whether the relative
513 contributions of burst size and frequency parameters vary between genes, we plotted the burst
514 size and frequency with confidence intervals for individual DV genes in the three clusters (Fig.
515 6f, Table S8). This revealed that DV genes have different dependencies on burst size and
516 frequency changes during bursts. We found that of the 47 PRO-seq identified DV genes with
517 a significant change in one or both kinetic values, 16 significantly changed in burst frequency
518 (e.g. *dpp*, *SoxN* and *twi*), 25 increased in burst size (e.g. *Meltrin* and *sna*) and 6 genes changed
519 in both burst size and frequency (e.g. *CG45263*) (Fig. 6f, Fig. S8d-f). There were more dorsal
520 ectoderm and neuroectoderm-specific genes that significantly increased in burst size than burst
521 frequency whereas more mesoderm-specific genes changed in burst frequency (Fig. S8e,f).

522 Since histone acetylation has been suggested to influence transcription by modulating
523 burst frequency^{68,69}, we sought to correlate tissue specific differences in burst kinetics to our
524 genomic datasets. For the enhancer-paired DV genes with a significant kinetic change ($n = 29$),
525 we found that the combined tissue-specific chromatin state at enhancers ($n = 58$) was a good
526 predictor of changes in burst frequency between tissues ($R^2 = 0.54$), and correlated better with
527 burst frequency changes than histone acetylation, CBP occupancy or chromatin accessibility
528 individually (Fig. 6g and Fig. S8g). In contrast, the chromatin state at promoters was poor at
529 predicting changes in burst frequency. Enhancer P-TEFb, BRD4/fs(1)h and eRNA

530 transcription also correlated significantly with burst frequency, but were not as good predictors
531 as the combined chromatin score (Fig. 6g). Differences in burst size between tissues could not
532 be explained as well as burst frequency by the chromatin state, but a significant correlation of
533 moderate strength was noted at enhancers (Fig. 6g and Fig. S8g, $R^2 = 0.25$). Interestingly,
534 loading of CycT at promoters was among the best predictors of burst size, indicating that
535 release from pausing may influence the burst size (Fig. 6g). We also explored if the enhancer-
536 promoter distance influenced the modulation of burst size or frequency during activation.
537 Interestingly, for a sub-class of DV enhancers located proximal (< 700 bp) to their target
538 promoters ($n = 22$) (Fig. 6h), bursts involved a significantly stronger shift in size than
539 frequency, whereas genes regulated by distal enhancers ($n = 115$) shifted in both burst size and
540 frequency upon activation (Fig. 6i).

541 To further explore DV gene bursts, we plotted the kinetics for genes partitioned into
542 classes based on whether they significantly changed in burst size ($n = 8$ genes, $n = 19$
543 enhancers), burst frequency ($n = 16$ genes, $n = 33$ enhancers) or both ($n = 5$ genes, $n = 6$
544 enhancers) in the cell cluster of expression compared to the inactive tissues (Fig. S8h-i). Burst
545 frequency (k_{on}) and burst size (k_{syn}/k_{off}) can reliably be inferred from scRNA-data⁶⁸, but how
546 well the individual k_{syn} and k_{off} parameters can be estimated is more uncertain. We observed
547 that increases in burst size appear to occur from lower off rates (k_{off}) and not from increases in
548 the rate of transcription (k_{syn}) in the tissue of activity (Fig. S8h-i). Although there is uncertainty
549 in these parameters, the data indicate that genes with increased burst size may remain in the
550 ON state for a longer period of time when they are activated. The parameters of promoter mean
551 occupancy ($k_{on}/(k_{on}+k_{off})$), which is the probability of a gene being in the ON state; switching
552 correlation time ($1/(k_{on}+k_{off})$), which is the correlation time of the switching process between
553 ON and OFF states, and the mean transcript synthesis rate ($(k_{syn}/k_{on})/(k_{on}+k_{off})$); the rate of
554 mRNA synthesis in the ON state⁷⁰, are also uncertain. Nevertheless, the data indicate that
555 increases in either burst size or frequency result in similar transcript synthesis rates and that
556 DV genes that change in both burst size and frequency achieve the highest rates of synthesis
557 (Fig. S8h-i). Examining the correlations between each parameter and the chromatin state
558 suggests that for genes changing in burst size, the enhancer chromatin state correlates well with
559 burst size ($R^2 = 0.48$) and promoter mean occupancy ($R^2 = 0.49$) (Fig. S8j). This suggests that
560 while the enhancer chromatin state primarily influences burst frequency, it can also modulate
561 transcriptional bursts through other parameters in a context-dependent manner.

562 Taken together, our transcriptome-wide inference of transcriptional bursting dynamics
563 during DV patterning show that DV genes have the capacity for high burst size, but a lower

564 burst frequency than non-DV genes, and that individual genes vary in their dependencies on
565 changes in size and frequency kinetics during bursts. Combining the burst data with our
566 comprehensive genome-wide epigenomic data reveals that the enhancer chromatin state
567 strongly modulates burst frequency, but has less, although still significant, influence on burst
568 size. The high burst size of DV genes is encoded by core promoter motifs that mediate strong
569 Pol II recruitment, as well as promoter-proximal pausing. Tissue-specific P-TEFb recruitment
570 ensures that bursts are only triggered in specific cells. Exploring the burst strategies employed
571 by DV genes reveals that despite varied dependencies of bursts for changes in frequency and
572 size, similar rates of transcript synthesis are achieved in cells where the DV genes are active.
573
574

575 **Discussion**

576 The establishment and maintenance of differential gene expression programs allows cells
577 within multicellular organisms that contain genomes with identical DNA sequences to form
578 distinct specialised tissues during embryogenesis. Yet, the interplay between chromatin state
579 and transcription is not entirely understood. Here we have provided a comprehensive genome-
580 wide assessment of chromatin state during *Drosophila* DV patterning, as measured by histone
581 acetylation, chromatin accessibility and CBP occupancy, and directly compared it to zygotic
582 transcription and Pol II activity status. The use of homogenous DV tissue mutants invariant in
583 chromatin state and transcription, allowed us to dissect the interplay between the two.
584 Consistent with data from mammals²⁹, we find that the chromatin state at promoters is largely
585 similar across tissues and cell types, but that enhancers are marked by tissue-specific chromatin
586 accessibility, histone acetylation and CBP occupancy.

587 This indicates that CBP fulfils distinct roles at enhancers and promoters. At enhancers,
588 CBP is recruited and activated by dimerization induced by tissue-specific TFs to catalyze
589 H3K27ac⁷¹, which activates enhancers and stimulates target gene transcription. At promoters,
590 CBP functions in the recruitment and establishment of a paused Pol II, possibly by interactions
591 with the general transcription factor TFIIB³³. These results suggest that detection of CBP at
592 the promoter is not simply a result of looping of the promoter to CBP-bound enhancers, as CBP
593 can be enriched at the promoters of DV genes in a tissue in which it is absent at the enhancer.
594 Further work is needed to elucidate the mechanisms underlying the deployment of distinct CBP
595 activities at promoters and enhancers.

596 Inactivity in non-expressing tissues is sometimes mediated by active repression.
597 Interestingly, we found that the chromatin state differs between two types of repressors, the
598 short-range repressor Sna and the long-range repressor Dl. Sna-mediated repression involves a
599 block of CBP-mediated H3K27ac, whereas repression by Dl is accompanied by Polycomb
600 silencing and H3K27me3. Since PRC1 directly inhibits the HAT activity of CBP⁷² and CBP-
601 mediated acetylation of the +1 nucleosome stimulates Pol II release into elongation⁷³, PcsGs
602 may also target CBP to impede pause release of Pol II.

603 Interestingly, our results show that Pol II pauses at the promoters of DV genes in a
604 tissue-invariant manner, irrespective of future transcription activation. Pol II promoter pausing
605 has previously been shown to be an important regulatory step in the transcription of
606 developmental genes and has been suggested to prime developmental genes for subsequent
607 activation¹⁰. Another function for Pol II pausing could be to promote synchronous gene
608 activation across cells in a tissue¹², and to minimize expression variability between cells in a

609 tissue²⁴. This property is largely defined by core promoter elements, with paused and
610 synchronous genes often having Initiator (Inr), downstream promoter element (DPE) and pause
611 button (PB) sequences, whereas TATA-containing genes show higher variability in expression
612 and are less paused^{10,24}.

613 We find that pause release of Pol II is the critical regulatory checkpoint that dictates
614 differential gene expression along the DV axis. Pausing is associated with the negative
615 elongation factor (NELF) and DRB sensitivity inducing factor (DSIF, consisting of Spt4 and
616 Spt5), and release of paused Pol II into productive elongation requires recruitment of the
617 positive transcription elongation factor b (P-TEFb) kinase⁵⁰. P-TEFb phosphorylates NELF,
618 DSIF and the C-terminal domain (CTD) of the Pol II largest subunit, allowing Pol II to escape
619 from the pause site. Thus, control of P-TEFb recruitment and activity could be the key event
620 in embryonic DV patterning. Indeed, we find that P-TEFb recruitment is spatially and
621 temporally linked to DV gene activity. Interestingly, REL-family proteins such as NF κ B
622 regulate genes by targeting P-TEFb and transcription elongation in mammals⁷⁴, suggesting
623 that the REL-protein Dl may also specify dorsoventral cell fates primarily by promoting pause
624 release. In addition to transcription factors such as Dl, enhancer chromatin state could also
625 influence pause release. We have previously shown that increased histone acetylation leads to
626 release from pausing at a subset of genes⁷³, so the correlation we find between H3K27ac and
627 tissue-specific gene activity may promote transcription elongation. It will be interesting to
628 further investigate how signals from the enhancer can modulate the activity of P-TEFb.

629 Once a gene is turned on, transcription is not continuous, but occurs in bursts. We found
630 that compared to other genes, DV genes have a low burst frequency but a high burst size. Thus,
631 many transcripts are produced per burst. This may result from an enrichment of core promoter
632 motifs in DV genes and high promoter-proximal pausing. However, pausing may also represent
633 an alternative OFF state that is not captured by a two-state model of transcription^{75,76}. The
634 majority of DV genes have a higher burst size in their tissue of expression compared to non-
635 expressing cells. The burst size is determined by the initiation rate and the off rate. Unlike gap
636 genes in *Drosophila* nc 13 embryos where the initiation rate is constant⁷⁰, our transcriptome-
637 wide analysis showed that initiation rates vary between genes and between cells for individual
638 genes. Still, the initiation rate (k_{syn}) is less variable than the off rate (k_{off}) for genes that increase
639 their burst size in the tissue of expression. Burst size has been shown to increase in response to
640 Notch signaling^{77,78}, primarily due to an increased burst duration. We cannot fully explain the
641 increase in burst size in cells where DV genes are expressed, but we note that proximal

642 enhancers and the presence of P-TEFb at the promoter may play a role, as well as the chromatin
643 state at enhancers. The difference in chromatin state at enhancers between cells has an even
644 larger impact on the burst frequency, consistent with previous findings^{68,69}, and with a role for
645 enhancers in modulating burst frequency⁷⁹.

646 Surprisingly, genes that are believed to be regulated in the same fashion have different
647 bursting kinetics. Both *twi* and *sna* are activated by the Dl transcription factor in the mesoderm,
648 but whereas *twi* has a higher burst frequency in the mesoderm compared to neuroectoderm and
649 dorsal ectoderm, *sna* expression is driven by a higher burst size. Further, both *dpp* and *zen* are
650 directly repressed by Dl in neuroectoderm and mesoderm, but whereas burst frequency is
651 increased for *dpp*, the *zen* burst size increases in dorsal ectoderm. Regulation of promoter
652 occupancy ($k_{on}/(k_{on} + k_{off})$), i.e. the proportion of time the promoter is active, has been
653 suggested to establish the expression domains of the *Drosophila* gap genes^{70,80}, and two DV
654 genes that respond to Dpp signaling⁸¹. Consistent with this, we find that promoter occupancy
655 is higher in cells where DV genes are expressed compared to other cell types both for genes
656 that change their burst size and for those that change in frequency. However, we note that the
657 kinetic parameters inferred in the framework of the two-state model may not be sufficient to
658 fully explain the gene expression difference between cell types. Modulation of the window of
659 time over which each cell transcribes the gene is a regulatory strategy that is independent of
660 bursting, and important for *even-skipped* stripe 2 formation⁸², which could also contribute to
661 differential DV gene transcription.

662 Overall, these results augment our current understanding of the interplay between the
663 formation of chromatin state and transcription (Fig. 6j). The data suggest that tissue-specific
664 DV enhancers and promoters are initially primed by increased accessibility across nuclei prior
665 to ZGA by the action of the maternally supplied pioneer factor Zelda^{61,83}. Increased
666 accessibility at enhancers is accompanied by CBP recruitment and histone acetylation, priming
667 the genes for future activation. This provides amenability for recruitment of Dl, with occupancy
668 occurring differentially across the DV axis of the embryo according to its nuclear concentration
669 and enhancer-specific differences in motif composition that affect binding affinity. Dl leads to
670 the tissue-specific recruitment of other TFs and co-regulators, including CBP and BRD4,
671 leading to the adoption of distinct enhancer chromatin states spatially within the embryo.
672 Concomitantly, promoters become accessible across tissues, permitting the recruitment of CBP
673 and Pol II by unidentified factors. Pol II initiates transcription and pauses before the Dl gradient
674 has formed and remains paused in all tissues. Recruitment and activation of P-TEFb, likely
675 mediated by Dl and distinct enhancer chromatin states, leads to tissue-specific pause release

676 and differential gene expression. The frequency of transcriptional bursts (k_{on}), is to a large part
677 determined by the enhancer chromatin state, whereas the burst size ($k_{\text{syn}}/k_{\text{off}}$) may also depend
678 on Pol II pausing and P-TEFb. We speculate that Pol II pausing confers a low off-rate, and that
679 P-TEFb activity is regulated and important for a high synthesis rate, leading to a high burst size
680 in the tissue of expression.

681

682

683

684

685 **Methods**

686

687 ***Drosophila* stock maintenance**

688 Mutant *Drosophila melanogaster* embryos composed entirely of presumptive dorsal ectoderm,
689 neuroectoderm or mesoderm were obtained from the fly stocks *gd⁷/winscy hs-hid*,
690 *Toll^{rm9/rm10}/TM6 e Tb Sb* and *Toll^{10B}/TM3 e Sb Ser/OR60*, respectively. One day old larvae laid
691 by *gd⁷/winscy hs-hid* were heat shocked for 1.5 hr at 37°C for two consecutive days to eliminate
692 *gd⁷* heterozygous animals and presumptive dorsal ectoderm mutant embryos collected from the
693 remaining *gd⁷* homozygous flies. *Toll^{rm9/rm10}* trans-heterozygous females were separated from
694 the stock and from them presumptive neuroectoderm embryos collected. *Toll^{10B}/TM3 e Sb Ser*
695 and *Toll^{10B}/OR60* heterozygotes that produce embryos composed of presumptive mesoderm
696 were separated from the stock. Survival assays were performed to confirm embryonic lethality
697 of *Toll* mutants. *yw; PCNA-eGFP*, a kind gift of Eric Wieschaus⁶⁰, and *w¹¹¹⁸* lines served as
698 controls (wild-type) for ChIP-qPCR and RT-qPCR experiments. Flies in which the *dorsocross*
699 (*doc*) locus E1 enhancer had been deleted (*doc enh del^{Δ/Δ}*) using a CRISPR (clustered regularly
700 interspaced short palindromic repeats)-Cas9 mediated deletion strategy and an intermediary
701 line carrying flippase recognition target (FRT) sites flanking the intact E1 enhancer (*doc enh^{+/+}*)
702 that served as a control, were kind gifts from Mounia Lagha⁸. Flies carrying *UASp-CycT* and
703 *Cdk9* transgenes were crossed with *w; alphaTub67C-GAL4::VP16* (Bloomington line 7062)
704 and used for maternal P-TEFb overexpression (OE) (see ‘Overexpression of P-TEFb in early
705 embryos’ methods section).

706 Stocks were kept on potato mash-agar food and maintained at 25°C with a 12-hour
707 light/dark cycle. Embryos were collected on apple juice plates supplemented with fresh yeast
708 and aged at 25°C for specific time ranges dependent on the specific experiment which is
709 detailed in the relevant methods section. Plates containing embryos collected for the first 2 h
710 each day were discarded to avoid contamination by older embryos withheld by females.
711 Collected embryos were dechorionated in diluted bleach, rinsed thoroughly in embryo wash
712 buffer (PBS, 0.1% Triton X-100) and processed further in a manner dependent on the specific
713 experiment which is detailed in the relevant methods sections.

714

715 **Overexpression of P-TEFb in early embryos**

716 Coding sequences for the P-TEFb subunits CycT and Cdk9 were PCR amplified and cloned
717 into the pUAS-K10.attB vector⁸⁴ by restriction digest and ligation (see Supplemental Table 9
718 for primer sequences) to produce the plasmids ‘*pUASp-CycT*’ and ‘*pUASp-Cdk9*’. CycT was

719 cloned into pUAS-K10.attB using the *KpnI* and *XbaI* restriction sites whereas Cdk9 was cloned
720 via *NotI* and *XbaI* sites. Plasmids were sequence verified, purified with the NucleoBond Xtra
721 Midi kit (Machery-Nagel, Cat. 740410.50) and pUASp-CycT inserted into the attP2 landing
722 site and pUASp-Cdk9 inserted into attP40 (FlyORF Injection Service). A double homozygous
723 *UASp-Cdk9* ; *UASp-CycT* stock was established and maternal overexpression achieved by
724 crossing virgin females with *w*; *alphaTub67C-GAL4::VP16* (Bloomington line 7062) males.
725 The resulting *UASp-Cdk9/alphaTub67C-GAL4::VP16* ; *UASp-CycT/* + females were
726 collected, crossed with male siblings and used for embryo collection. For RNA *in situ*
727 hybridization and ChIP-qPCR, P-TEFb OE and wild-type (*w¹¹¹⁸*) embryos were collected for
728 2 h and aged a further 2 h (2-4 h AEL) and for RNA extraction and RT-qPCR embryos were
729 collected for 1 h and aged a further 1.5 h (1.5-2.5 h AEL).

730

731 **RNA *in situ* hybridization**

732 RNA *in situ* hybridization was performed on wild-type (*w¹¹¹⁸*), *gd⁷*, *Toll^{rm9/rm10}* and *Toll^{10B}* (2-
733 4 h AEL) embryos using digoxigenin-labeled antisense RNA probes against *dpp*, *ind*, *twi* and
734 *shn*. Probes against *dpp*, *zen*, *ind*, *sog*, *twi* and *sna* were used on wild-type (*w¹¹¹⁸*) and P-TEFb
735 OE (2-4 h AEL) embryos and a probe against *psq* was used on wild-type (*w¹¹¹⁸*) (2-4 h AEL)
736 embryos. RNA *in situ* hybridization was performed as previously described^{85,86}. Embryos were
737 observed on a Leica DMLB 100T microscope and images taken on a Leica DMC2900 camera.
738 We counted wild-type (wt) and P-TEFb OE (OE) embryos stained for *dpp* (wt *n* = 143, OE *n*
739 = 206), *zen* (wt *n* = 119, OE *n* = 197), *ind* (wt *n* = 139, OE *n* = 178), *sog* (wt *n* = 155, OE *n*
740 = 131), *twi* (wt *n* = 128, OE *n* = 86), and *sna* (wt *n* = 180, OE *n* = 112) manually for normal and
741 ectopic signal and calculated the odds ratio alongside Fisher's exact test to measure the
742 significance of differences in the number of ectopically stained embryos between genotypes.
743 Images of RNA *in situ* hybridization for *zen*, *ush*, *SoxN*, *Meltrin*, *twi*, *sna* and *htl* in wild-type
744 embryos were obtained from the BDGP database⁸⁷⁻⁸⁹.

745

746 **Precision run-on sequencing (PRO-seq)**

747 PRO-seq was performed on *Toll* mutant embryos collected for 0.5 h and aged for a further 2.5
748 h (2.5-3 h AEL) or 4.5 h (4.5-5 h AEL) and both PRO-seq and qPRO-seq were performed on
749 naïve *yw*; *PCNA-eGFP* embryos collected for 20 min, aged for 1 h (60-80 min AEL) and hand-
750 sorted according to the nuclear cycle observed by the eGFP signal with older embryos
751 discarded. Collected embryos were dechorionated in dilute bleach and rinsed thoroughly in

752 embryo wash buffer (PBS, 0.1% Triton X-100) before being flash-frozen in liquid nitrogen and
753 stored at -80°C.

754 PRO-seq and qPRO-seq were performed as previously described^{18,19}. Briefly, embryos
755 were resuspended in cold nuclear extraction buffer A (10 mM Tris-HCl pH 7.5, 300 mM
756 sucrose, 10 mM NaCl, 3 mM CaCl₂, 2 mM MgCl₂, 0.1% Triton X, 0.5 mM DTT, protease
757 inhibitor cocktail (Roche) and 4 u/ml RNase inhibitor (SUPERaseIN, Ambion)), transferred to
758 a dounce homogenizer and dounced with the loose pestle for 20 strokes. To remove large
759 debris, the suspension was passed through mesh followed by douncing with a tight pestle for
760 10 strokes. Nuclei were pelleted at 700 g for 10 min at 4°C and washed twice in buffer A and
761 once in buffer D (10 mM Tris-HCl pH 8, 25% glycerol, 5mM MgAc₂, 0.1 mM EDTA, 5 mM
762 DTT). For PRO-seq, isolated nuclei corresponding to approximately 10 million cells, and for
763 qPRO-seq from 1 million cells, were resuspended in buffer D and stored at -80°C. Nuclear run-
764 on assays were performed in biological duplicates exactly as previously described^{18,19,33}. PRO-
765 seq and qPRO-seq libraries were sequenced (single-end 1 × 75 bp) on the Illumina NextSeq
766 550 platform at the BEA core facility, Karolinska Institutet, Stockholm.

767

768 **Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq)**

769 ATAC-seq was performed on *Toll* mutant embryos collected for 0.5 h and aged accordingly to
770 achieve three developmental time points: 2.5-3 h, 3.5-4 h and 4.5-5 h AEL. For each time point,
771 10 embryos per replicate presenting the correct morphology for the developmental stage sought
772 were immediately hand-sorted. Hand-sorted embryos were dechorionated in dilute bleach,
773 rinsed thoroughly in embryo wash buffer (PBS, 0.1% Triton X-100) and crude nuclear extracts
774 isolated by homogenizing the embryos using a motor pestle in ATAC lysis buffer (10 mM Tris
775 pH 7.4, 10 mM NaCl, 3 mM MgCl₂ and 0.1% IGEPAL CA-630) and centrifugating at 700 g
776 for 10 min. The nuclear pellet was resuspended in 22.5 µl of ATAC lysis buffer, 2.5 µl Tn5
777 (Tegment DNA Enzyme 1 (TDE1) (Illumina)) and 25 µl Tegment DNA Buffer (Illumina) and
778 subjected to tagmentation at 37°C on a thermomixer at 1,000 rpm. Transposition was blocked
779 by the addition of 1% SDS and DNA purified with Agencourt AMPure XP beads (Beckman
780 Coulter, A63881) according to the manufacturer's instructions using a 2:1 ratio of beads to
781 sample. Libraries were prepared as previously described⁹⁰. Briefly, tagmented DNA was PCR
782 amplified using 1x Phusion® High-Fidelity PCR Master Mix with GC Buffer (NEB) and 1.25
783 µM i5 and i7 PCR primers (Nextera® Index Kit (Illumina)) with the following PCR
784 amplification conditions: 72°C for 5 min, followed by 10 cycles of 98°C for 10 seconds, 65°C
785 for 1 min and 15 seconds, then 72°C for 1 min. Amplified libraries were purified with

786 Agencourt AMPure XP beads with a 1.5:1 ratio of bead to sample volume. Libraries prepared
787 from biological triplicates were sequenced paired-end (2 x 150 bp) on the Illumina NovaSeq
788 platform at SciLifeLab, Stockholm.

789

790 **Chromatin immunoprecipitation sequencing (ChIP-seq) and ChIP-qPCR**

791 ChIP-seq and ChIP-qPCR were performed on *Toll* mutant embryos collected for 2 h and aged
792 for a further 2 h (2-4 h AEL) and ChIP-qPCR was also performed on *doc* enh del^{Δ/Δ} and *doc*
793 enh^{+/+} (2-4 h AEL) control embryos and P-TEFb OE and wild-type (*w¹¹¹⁸*) (2-4 h AEL)
794 embryos. Formaldehyde crosslinking and chromatin preparation of embryos was performed as
795 described previously ⁹¹. Briefly, dechorionated embryos were crosslinked in a mixture of 2 ml
796 fixation buffer (PBS, 0.5% Triton X-100) and 6 ml heptane supplemented with 100 µl of 37%
797 formaldehyde (Sigma-Aldrich, F8775) for 15 min at room temperature with rotation. Fixation
798 was quenched by the addition of PBS supplemented with 125 mM glycine and crosslinked
799 embryos were washed 3 times in wash buffer (PBS, 0.5% Triton X-100), snap frozen in liquid
800 nitrogen and stored at -80°C. For chromatin preparation, embryos were homogenized in a glass
801 dounce homogenizer by 20 strokes with a tight pestle in A1 buffer (15 mM HEPES pH 7.6, 15
802 mM NaCl, 60 mM KCl, 4 mM MgCl₂, 0.5 mM DTT, 0.5% Triton X-100 and protease inhibitor
803 tablets (Roche)), centrifuged at 3500 g for 5 min at 4°C and the supernatant discarded. The
804 remaining nuclear pellet was resuspended in 200 µl of sonication buffer (15 mM HEPES pH
805 7.6, 140 mM NaCl, 1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0, 0.1% sodium deoxycholate,
806 1% Triton X-100 and protease inhibitor tablets (Roche)) supplemented with 0.5% SDS and
807 0.2% n-lauroylsarcosine and sonicated using a Bioruptor (Diagenode) with high power settings
808 to obtain an average fragment size distribution of 200-500 bp, Sonicated chromatin was
809 centrifuged at 13,000 rpm for 10 min at 4°C and diluted 5-fold in sonication buffer to reduce
810 the concentration of detergents.

811 For chromatin from *Toll* mutant embryos, immunoprecipitations (IPs) were performed
812 with 10 µg rabbit anti-CBP (homemade, ¹⁶), 2 µg rabbit anti-CycT and anti-Cdk9 (both kind
813 gifts of Kazuko Hanyu-Nakamura ⁹²), and with 2 µg rabbit anti-H3K27ac (Abcam, ab4729)
814 (also described in ⁷) and 5 µg mouse anti-H3K27me3 (Abcam, ab6002) on chromatin from the
815 *Toll^{rm9/rm10}* mutant. H3K27ac ChIP-seq data from *gd*⁷ and *Toll^{10B}* mutants used in this study
816 were generated by ¹⁴. IPs on chromatin from *doc* enh del^{Δ/Δ} and *doc* enh^{+/+} control embryos
817 were performed with CycT, rabbit anti-BRD4/fs(1)h (long isoform) (a gift of Renato Paro,
818 kindly provided by Nicola Iovino) ⁹³), CBP, H3K27ac, H3K27me3 and rabbit anti-H3 (Abcam,
819 ab1791) antibodies. Chromatin from P-TEFb OE and wild-type (*w¹¹¹⁸*) embryos was

820 immunoprecipitated with anti-CycT. Chromatin was incubated with antibodies overnight at
821 4°C and equal amounts of Protein A and G Dynabeads (Invitrogen), pre-blocked with BSA (1
822 mg/ml), were incubated with the samples for 4 h at 4°C. Chromatin corresponding to 10% of
823 the amount in each IP was withdrawn to serve as an input for qPCR. Samples were subjected
824 to 10 min washes with Wash A (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 140 mM NaCl,
825 0.1% SDS, 0.1% Sodium Deoxycholate and 1% Triton X-100), Wash B (Wash A adjusted to
826 500 mM NaCl), Wash C (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 250 mM LiCl, 0.5%
827 Sodium Deoxycholate and 0.5% IGEPAL CA-630) and Tris-EDTA (TE) buffer. Beads were
828 resuspended in 100 µl TE and treated with RNase A (20 µg/ml) at 55°C for 30 min before SDS
829 (to 0.75%) and Tris-HCl (to 50mM) were added and crosslinks reversed at 65°C for overnight.
830 Eluted ChIP DNA was treated with Proteinase K at 55°C for 2 h and purified with the ChIP
831 DNA Clean & Concentrator kit (ZymoResearch, D5205).

832 ChIP-sequencing was performed using 2-5 ng of ChIP DNA from *Toll* mutant IPs with
833 CBP, H3K27ac and H3K27me3 antibodies (only *Toll*^{rm9/rm10} for H3K27ac and H3K27me3
834 ChIP DNA) in biological duplicates. Libraries were prepared with the NEBNext® Ultra II
835 DNA Library Prep Kit for Illumina (NEB, E7645L) and single-end (1 x 75 bp) sequenced on
836 the Illumina NextSeq 550 platform at the BEA core facility, Karolinska Institutet, Stockholm.

837 ChIP DNA from IPs and inputs on *Toll* mutant chromatin (CycT), *doc* enh del^{Δ/Δ} and
838 *doc* enh^{+/+} control chromatin (CycT, BRD4/fs(1)h, CBP, H3K27ac, H3K27me3 and H3) and
839 P-TEFb OE and wild-type (*w*¹¹¹⁸) chromatin (CycT) were analyzed by qPCR on a CFX96 Real-
840 Time System (BioRad). qPCR reactions were carried out using 2 µl of ChIP DNA as a template
841 with 300 nM primers and 5X HOT FIREPol® EvaGreen® qPCR Mix Plus (Solis BioDyne) in
842 duplicate. All primers used in this study are listed in Supplemental Table S9. The percentage of
843 input precipitated for each target was determined by comparing the average Cq to that of the
844 input and the level of enrichment normalized to the signal at intergenic loci devoid of chromatin
845 factors and histone modifications. For H3K27ac and H3K27me3, enrichment was further
846 normalized to the occupancy of H3. Due to unexpected variations in the intergenic control
847 signal between CycT IPs on P-TEFb OE and wild-type (*w*¹¹¹⁸) chromatin, data were presented
848 as percent (%) input precipitated.

849

850 **CUT&Tag**

851 CUT&Tag was performed on *Toll* mutant embryos collected for 2 h and aged for a further 2 h
852 (2-4 h AEL) and *yw*; *PCNA-eGFP* embryos collected for 20 min and aged for 1 h (60-80 min
853 AEL, nc 7-9), 30 min and aged for 1.5 h (1.5-2 h AEL, nc 11-13) and 2 h and aged for 2 h (2-

854 4 h AEL, nc 14). Hand-sorting was performed with the nuclear cycle observable by the eGFP
855 signal with older embryos discarded. CUT&Tag was performed essentially as described by ⁹⁴.
856 Collected embryos were dechorionated, rinsed in embryo wash buffer (PBS, 0.1% Triton X-
857 100) and crude nuclear extracts prepared using a glass douncer and loose pestle in Nuclear
858 Extraction buffer (20 mM HEPES pH 7.9, 10 mM KCl, 0.5 mM spermidine, 0.1% Triton X-
859 100, 20% glycerol with protease inhibitor cocktail (Roche)) ⁹⁵ and centrifuged at 700 g for 10
860 min at 4°C. The nuclear pellets were resuspended in Nuclear Extraction buffer. Nuclei
861 corresponding to 50 embryos per reaction (2-4 h AEL), 100 embryos (1.5-2 h AEL) or 200
862 embryos (60-80 min AEL) were incubated with 30 µl of BioMag®Plus Concanavalin A beads
863 (Polysciences) (prepared in Binding buffer (20 mM HEPES pH 7.5, 10 mM KCl, 1mM CaCl₂,
864 and 1 mM MnCl₂)) on a nutator for 10 min at 4°C. Nuclei-bead complexes were resuspended
865 in 100 µl Antibody buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM spermidine, 0.05%
866 digitonin, 2 mM EDTA pH 8.0 and 0.1% BSA supplemented with protease inhibitor cocktail
867 (Roche)). For *Toll* mutant CUT&Tag, 1 µl of rabbit anti-BRD4/fs(1)h, rabbit anti-CycT, rabbit
868 anti-Cdk9, rabbit anti-Rpb3 (a kind gift of John Lis), guinea pig anti-Dorsal (a kind gift of
869 Christos Samakovlis) and rabbit anti-RNA Polymerase II CTD repeat YSPTSPS (phosphor S5)
870 (5SerP) (Abcam, ab5131) overnight at 4°C. For *yw*; *PCNA-eGFP* CUT&Tag, 1 µl of rabbit
871 anti-BRD4/fs(1)h, rabbit anti-Cdk9 and rabbit anti-CBP. Following overnight incubation,
872 tagmentation was performed using pA-Tn5 (Protein Science Facility, KI, Stockholm).
873 Tagmented DNA was PCR amplified using custom i5 and i7 PCR primers and Phusion® High-
874 Fidelity PCR Master Mix with GC Buffer (NEB). PCR conditions were: 72°C for 5 min, 98°C
875 for 30 s, followed by thermocycling (98°C for 10 s and 63°C for 10 s) for 13 cycles and final
876 extension at 72°C for 1 min. Amplified libraries were purified using Agencourt AMPure XP
877 beads (Beckman Coulter) (1.1:1 bead to sample volume ratio). Libraries were paired-end (2 x
878 37 bp) sequenced on an Illumina NextSeq 550 platform at the BEA core facility, Karolinska
879 Institutet, Stockholm. The low read counts obtained from sequencing for the CUT&Tag
880 samples *gd*⁷ 2to4h CUT&Tag CycT Replicate 2, *gd*⁷ 2to4h CUT&Tag BRD4 Replicate 2 and
881 *Toll*^{10B} 2to4h CUT&Tag D1 Replicate 2 indicated these reactions had failed so they were
882 excluded from the subsequent analysis.

883

884 **RNA extraction and RT-qPCR**

885 Total RNA was extracted from *doc* enh del^{Δ/Δ} and *doc* enh^{+/+} (2-4 h AEL) and *P*-TEFb OE and
886 wild-type (*w*¹¹¹⁸) (1.5-2.5 h AEL) embryos. Dechorionated embryos were homogenized in cold
887 PBS with a plastic pestle and RNA extracted using TRIzol LS (Invitrogen). Total RNA was

888 purified and concentrated using the RNeasy MinElute Cleanup kit (Qiagen) according to the
889 manufacturer's instructions. Purified RNA (1.5 µg) was treated with DNase I (Sigma-Aldrich)
890 to eliminate contaminating genomic DNA and converted to cDNA with the High-Capacity
891 RNA-to-cDNA kit (ThermoFisher Scientific) according to the manufacturer's instructions. RT-
892 qPCR was performed on a CFX96 Real-Time System (Biorad) using 2 µl of cDNA as template
893 with 300 nM primers and 5X HOT FIREPol® EvaGreen® qPCR Mix Plus (Solis BioDyne) in
894 duplicate. The delta-delta Ct method was used to quantify mRNA levels relative to RpL32
895 (RNA from *doc* enh del^{Δ/Δ} and *doc* enh^{+/+} embryos) and 28S rRNA (RNA from P-TEFb OE
896 and wild-type (*w¹¹¹⁸*)). All primers used in this study are listed in Supplemental Table S9.

897

898 **PRO-seq data analysis**

899 PRO-seq and qPRO-seq reads were mapped to the *Drosophila melanogaster* (dm6) genome
900 assembly using Bowtie2 (v.2.3.5) with the default program parameters ⁹⁶. Library mapping
901 statistics are listed in Supplemental Table S10. Strand separated RPKM normalized (bigwig)
902 coverage tracks from individual replicates were generated using the deepTools (v.3.5.1)
903 package 'bamCoverage' using the default parameters (binSize = 2 (bases), normalizeUsing =
904 RPKM) ⁹⁷. Strand separated files of the mean RPKM signal from both replicates were produced
905 by first merging the read alignment files produced by Bowtie2 from each replicate using the
906 SAMtools package 'samtools merge' and then bigwig files produced by 'bamCoverage'
907 (deepTools). To allow for simultaneous genome browser visualization of the signal from the
908 pause site and gene body at genes of interest, the bin size was extended to 10 bp when producing
909 the merged bigwig files. Read counts per gene (CDS) were extracted with featureCount ⁹⁸.

910

911 **ChIP-seq, ATAC-seq and CUT&Tag data analysis**

912 ChIP-seq, ATAC-seq and CUT&Tag reads were mapped to the *Drosophila melanogaster*
913 (dm6) genome assembly using Bowtie2 (v.2.3.5) with the default program parameters ⁹⁶.
914 Library mapping statistics are listed in Supplemental Table S10. RPKM normalized (bigwig)
915 coverage tracks from individual replicates were generated using the deepTools (v.3.5.1)
916 package 'bamCoverage' using the default parameters (binSize = 1 (bases), normalizeUsing =
917 RPKM) ⁹⁷. The mean RPKM signal from both replicates were produced by first merging the
918 read alignment files produced by Bowtie2 from each replicate using the SAMtools package
919 'samtools merge' and then bigwig files produced by 'bamCoverage' (deepTools). Peaks were
920 called for *Toll* mutant ATAC-seq and CBP and H3K27ac ^{7,13,14} ChIP-seq using the Genrich
921 peak caller (version 0.6) (<https://github.com/jsh58/Genrich#contact>) with the default program

922 parameters. Read counts per gene (CDS), promoter and enhancer (all peaks called for CBP not
923 overlapping the TSS of genes) were extracted with featureCount⁹⁸.

924

925 **Analysis of previously published datasets**

926 In addition to the datasets generated in this study we reanalyzed the following published
927 datasets: ChIP-seq for H3K27ac and H3K27me3 from *gd*⁷ and *Toll*^{10B}, Zen and Mad from *gd*⁷
928 embryos, Twi from *Toll*^{10B}, Sna, Pc and GAF from wild-type (Oregon-R) (2-4 h AEL) embryos
929 (GEO: GSE68983)¹⁴⁻¹³; ChIP-seq for H3K27ac from *Toll*^{rm9/rm10} (2-4 h AEL) embryos
930 (ArrayExpress: E-MTAB-9303) and scRNA-seq from wild-type (*PCNA-eGFP* and *w*¹¹¹⁸) and
931 *Toll* mutant (2.5-3.5 h AEL) embryos (ArrayExpress: E-MTAB-9304)⁷; ChIP-nexus for Dl
932 from wild-type (Oregon-R) (2-4 h AEL) embryos (GEO: GSE55306)⁴¹; ChIP-seq for Zld from
933 nc 8, nc 13 and nc 14 wild-type embryos (GEO: GSE30757) (Harrison et al., 2011); ChIP-seq
934 for Zld from wild-type (2-3 h AEL) embryos (GEO: GSE65441)⁶¹; ChIP-seq for Opa from
935 wild-type (ZH-86Fb) nc 14 (4 h AEL) and ATAC-seq from nc 14 wild-type (ZH-86Fb), Zld
936 maternal RNAi and opa maternal RNAi embryos (GEO: GSE140722)⁶³; CLAMP ChIP-seq
937 for CLAMP from wild-type (MTD-Gal4, Bloomington line 31777) (2-4 h AEL) embryos
938 (GEO: GSE152598) and ATAC-seq from wild-type (MTD-Gal4, Bloomington line 31777) and
939 CLAMP maternal RNAi (2-4 h AEL) embryos (GEO: GSE152596)⁶⁴; ATAC-seq from control
940 (His2AV-RFP; sfGFP-GAF) and GAF^{deGradFP} (His2Av-RFP/nos-degradFP; sfGFP-GAF) (2-
941 2.5 h AEL) embryos (GEO: GSE152771)⁶⁵; ChIP-seq for H3K27ac, H3K18ac, H4K8ac,
942 H3K9ac, H3K4me1 and H3K4me3 ChIP-seq from wild-type (Oregon-R) (nc 8, nc 12 and nc
943 14 (early and late)) embryos (GEO: GSE58935)⁶⁶; and ATAC-seq from wild-type embryos nc
944 11-13 (GEO: GSE83851)⁶⁰.

945 Reads for the publicly available data were mapped to the *Drosophila melanogaster*
946 (dm6) genome assembly using Bowtie2 (v.2.3.5) with the default program parameters⁹⁶.
947 RPKM normalized (bigwig) coverage tracks from individual replicates were generated using
948 the deepTools (v.3.5.1) package ‘bamCoverage’ using the default parameters (binSize = 1
949 (bases), normalizeUsing = RPKM)⁹⁷. For ATAC-seq data from wild-type embryos⁶⁰, bigwig
950 files of the mean signal for replicates and the mean signal across each nuclear cycle were
951 produced using the deepTools (v.3.5.1) package ‘bigwigCompare’ using the default
952 parameters. For ChIP-seq data for various histone modifications⁶⁶ and ATAC-seq data for
953 from various pioneer factor perturbations⁶³⁻⁶⁵ we used processed data sets generated in the
954 original publications.

955

956 **Quality control for PRO-seq, ATAC-seq, ChIP-seq and CUT&Tag**

957 For *Toll* mutant PRO-seq, ATAC-seq, ChIP-seq and CUT&Tag experiments, Principal
958 Component Analysis (PCA) was done on the normalized read counts for all genes, promoters
959 and enhancers (peaks called for CBP not overlapping the TSS of genes) as a quality control
960 (QC) step to make sure that most of the variation in the data could be explained by the
961 difference in genotype between the mutants. Based on the scores of the PCA, a subset of the
962 principal components (PCs) were identified that separated the *Toll* mutant samples in the PC
963 space.

964

965 **Identification of tissue-specific regions linked to DV regulated genes**

966 Based on the PCs identified in the QC, three latent linear vectors, one for each *Toll* mutant,
967 were created. For each *Toll* mutant, the vectors pass through origo and the mean value of the
968 *Toll* mutant samples PC scores with the positive direction towards the mean value of the *Toll*
969 mutant. For each region (genes, promoters and enhancers), three latent vector scores, one for
970 each *Toll* mutant, were calculated. Each score is the position on the *Toll* mutant latent vector
971 that is the closest to the regions PCA loading. For each *Toll* mutant the scores were then
972 normalized, by removing the mean and dividing by the standard deviation of all the regions.
973 For genes, the regions represent all expressed genes, for promoter it represents the regions
974 around the expressed genes' TSS and for enhancers it represents the peak regions identified
975 from the CBP ChIP-seq peak calling.

976

977 **Identification of differentially expressed DV regulated genes and pausing analysis**

978 Genes with less than 10 reads mapping to the gene body were removed from the analysis. Count
979 data for the remaining genes were normalized using DEseq2⁹⁹. Log₂ normalized gene levels
980 were used for quality control and latent vector scores as described above. To test the validity
981 of using a latent vector approach and select a cutoff, ROC analysis was done. The positive set,
982 for the ROC analysis, of previously known DV regulated genes identified from microarray data
983 and validated by one other method were obtained from¹⁰⁰. After ROC analysis DV genes were
984 selected with a latent vector score above 3. A list of AP regulated genes (*n* = 31) used as a
985 comparative data set to the DV genes were obtained from Saunders, et al.¹⁰¹. Genes zygotically
986 expressed at nc 7-9 (*n* = 20), nc 9-10 (*n* = 63), syncytial blastoderm (*n* = 946) and cellular
987 blastoderm (*n* = 3540) stages of early *Drosophila* embryogenesis were obtained from
988 Kwasnieski, et al.²².

989 To examine Pol II promoter proximal pausing, the gene body read count (GBC, using
990 the CDS counts) and promoter count (PC, from 50 bp upstream of the TSS to 100 bp
991 downstream of the TSS) were determined for each annotated transcript. The pausing index (PI),
992 which is a ratio describing the magnitude of pausing, was calculated by dividing the PC by the
993 sum of the PC and GBC. For genes with multiple isoforms, the transcript with the highest
994 average GBC divided by the length of the CDS was selected. Statistical analysis for
995 comparisons between the gene expression level and PI of the same gene class between different
996 *Toll* mutants were performed with the Wilcoxon signed-rank test, whereas comparisons
997 between different gene classes used the Wilcoxon rank-sum test.

998

999 **Identification of tissue-specific enhancers linked to DV regulated genes**

1000 To identify tissue specific enhancers regions, identified by CBP ChIP-seq peak calling, were
1001 analysed for enrichment of reads from CBP ChIP-seq, H3K27ac ChIP-seq and ATAC-seq *Toll*
1002 mutant experiments described above. For each approach regions with less than 10 reads were
1003 removed from further analysis and the remaining regions were normalised with DEseq2 rlog
1004 and used for PCA analysis. Number of PC for each approach was manually selected, PC 1 to 3
1005 for ATACseq and PC 1 and 2 for CBP and H2K27ac and used for latent vector score
1006 calculations as described above. Combined tissue-specific enhancer and promoter latent vector
1007 scores were calculated by summing the CBP, H3K27ac and the ATAC-seq enhancer or
1008 promoter latent vector scores for each *Toll* mutant. Only the enhancer regions among the top
1009 5% were considered potential enhancers. When assigning putative enhancers to DV regulated
1010 genes, a requirement was that they resided in the same topologically associated domain (TAD)
1011 (domain boundaries were from Hi-C data in 3-4 h AEL embryos ^{7,42}).

1012 To validate the functional activity of the identified tissue-specific DV enhancers, we
1013 lifted annotation terms ($n = 31$) associated with the *in vivo* activity of 7793 enhancer reporter
1014 lines driven by non-coding genomic fragments in stage 4 to 6 *Drosophila* embryos ³². We then
1015 measured the enrichment of annotation terms for reporter lines driven by fragments
1016 overlapping DV enhancers and compared to those overlapping all other annotated CBP peaks.
1017 Only terms with P -values < 0.005 (Fisher's exact test) in at least one of the *Toll* mutant
1018 enhancers were kept.

1019 To assess the quality of the enhancer identification strategy we performed receiver
1020 operating characteristic (ROC) curve analysis with all non-assigned enhancer regions as the
1021 negative set and the assigned tissue specific enhancers that overlapping non-coding genomic

1022 fragments identified to have DV-regulated activity in an enhancer-reporter assay ³² as the
1023 positive set.

1024

1025 **Promoter and enhancer motif analysis**

1026 We scanned DV promoters for putative core promoter elements from the CORE database and
1027 compared the proportion of promoters with motifs between DV promoters and all promoters in
1028 the database ²⁶. To *de novo* identify promoter motifs we scanned DV regulated promoters for
1029 ungapped enriched motifs using the Multiple EM for Motif Elicitation (MEME) tool from the
1030 MEME suite (<https://meme-suite.org/meme>). Long enriched motifs were identified with a
1031 threshold of 31 nt (-minw 31). For the other motifs we required that the length to be \leq 30 nt (-
1032 maxw 30). Motifs with an e-value less than 0.005 were kept for further analysis. The motifs
1033 were compared, using TOMTOM in the MEME-suite, against the motifs in the JASPAR
1034 Insects CORE redundant TF motifs database (version 2020). All of the *de novo* identified
1035 motifs with *P*-values less than 0.005 were renamed based on matches to known motifs from
1036 the JASPAR database. Motifs that fitted the Inr and the DPE were assigned as Inr or Inr and
1037 DPE. The MEME suite tool FIMO was used to search DV, AP and all other promoters for
1038 occurrences of the identified motifs. Log₂ odds ratios were measured for the different motifs.
1039 See Table S3 for the *de novo* identified motifs at DV promoters.

1040 The MEME tool was also used to identify motifs enriched at the tissue-specific DV
1041 enhancers. For each enhancer class, we scanned for motifs between 5-mer and 12-mer in width,
1042 occurring with any number of repetitions within each sequence. We then compared the *de novo*
1043 identified motifs to known *Drosophila* motifs across the combined *Drosophila* databases from
1044 the MEME suite using TOMTOM with the default parameters (Table S5). Enriched known
1045 motifs, from the JASPAR Insects CORE redundant TF motifs database (version 2020), were
1046 identified using the function ‘motifEnrichment’ from the PWMEnrich 4.26.0 R package
1047 (<https://bioc.ism.ac.jp/packages/3.11/bioc/html/PWMEnrich.html>). Five hundred randomly
1048 selected CBP peaks were used as a background distribution. All motifs with a raw enrichment
1049 score of > 1.5 and a *P*-value < 0.05 in at least one of the enhancer classes were kept as enriched
1050 motifs (Table S6).

1051

1052 **Examining DV enhancer and promoter overlaps with peaks called from publicly available 1053 data**

1054 We performed MACS2 peak calling ^{102,103} with the default program parameters on the
1055 alignments produced with Bowtie2 from the published ChIP-nexus for Dorsal (Dl) ⁴¹ and ChIP-

1056 seq for Zen, Mad, Twi and Sna^{14 13}. From the MACS2 peak calling results, we selected the
1057 500 (Dl and Sna) or 1000 (Zen, Mad and Twi) strongest sites to ensure only high-confidence
1058 peaks would be used in the analysis. BEDTools intersect¹⁰⁴ was used to identify DV enhancers
1059 and promoters that overlapped the called peaks. For measuring overlaps, promoter regions were
1060 defined as (TSS \pm 750 bp). DV genes identified from *Toll* mutant PRO-seq expressed
1061 specifically in the dorsal ectoderm with a Dl peak within \pm 15 kb of the TSS were selected as
1062 Dl-repressed genes ($n = 6$). Sna repression targets ($n = 13$) were identified as the genes
1063 expressed in the neuroectoderm with Sna and Dl co-bound site within \pm 15 kb of the TSS.
1064 Overlaps were also made using a list of genomic coordinates for known *Drosophila* Polycomb
1065 Response Elements (PREs) compiled by⁵⁸ and lifted to the dm6 *Drosophila* reference genome
1066 using the UCSC LiftOver tool. To preserve the original spike-in normalizations used for the
1067 ChIP-seq data from histone marks across early nuclear cycles⁶⁶, we used the coordinates for
1068 peaks called in the original paper using the dm3 *Drosophila* reference genome. We lifted peaks
1069 for DV and non-DV enhancers and promoters from dm6 to dm3 using the UCSC LiftOver tool.
1070 For Zld ChIP-seq across early nuclear cycles⁶² we also used the peaks called in the original
1071 paper from the dm3 reference genome.

1072

1073 **Measuring changes in chromatin accessibility at DV enhancers and promoters after 1074 pioneer factor perturbation**

1075 To quantify changes in ATAC-seq signal at DV enhancers and promoters from publicly
1076 available data for pioneer factor perturbations⁶³⁻⁶⁵, the signal at DV and shuffled enhancers
1077 and promoters (TSS \pm 500 bp) (obtained using BEDTools ‘shuffle’¹⁰⁴) was counted using the
1078 deepTools ‘BigWigSummary’ tool⁹⁷ and the log₂ fold change (perturbation/control) in signal
1079 measured. Boxplots were produced in R using the ggplot2 package and significant differences
1080 in the change in accessibility between DV and shuffled enhancers and promoters was measured
1081 with the Wilcoxon rank-sum test.

1082

1083 **Uniform Manifold Approximation and Projection (UMAP) clustering of scRNA-seq data**

1084 We selected the cells in scRNA-seq from wild-type (*PCNA-eGFP*) embryos that had been
1085 originally assigned to DV-relevant clusters (ectoderm1, ectoderm2, ectoderm3, neural1,
1086 neural2, mesoderm1 and mesoderm2, $n = 2787$) based on clustering using the shared nearest
1087 neighbor (SNN) approach from the Seurat package (version 4.1.0)^{7,105,106}. From the scRNA-
1088 seq data in the selected cells, a new principal component space was constructed using the
1089 PRO-seq identified DV genes as features to separate the cells. SNN clustering was performed

1090 on the first 10 PCs with a clustering resolution of 0.3. Identified clusters were annotated based
1091 on the expression levels of PRO-seq identified DV genes. Based on the expression of DV
1092 marker genes the derived clusters were named Dorsal ectoderm (*dpp*, *Doc1* and *ush* marker
1093 genes, $n = 1396$), early (*ind*, *sog* and *brk* marker genes, $n = 1392$) and late (older neural cells,
1094 *scrt*, *ase* and *nerfin-1* marker genes, $n = 2367$) Neuroectoderm, early (*twi* and *sna* marker genes,
1095 $n = 2333$) and late (older mesoderm or myoblasts, *Mef2*, *meso18E*, *sns* and *sing* marker genes,
1096 $n = 1448$) Mesoderm and a common cluster of cells ($n = 851$) that could not be separated
1097 according to the expression of the DV genes (Table S7). Average expression levels within each
1098 cluster were obtained for 160 of the 195 DV regulated genes, 26 of the 31 AP regulated genes
1099 and 1819 non-DV genes (Table S7). Uniform Manifold Approximation and Projections
1100 (UMAPs) were constructed using the default settings to visualize the scRNA-seq data.

1101

1102 **Inference of transcriptional bursting kinetics from scRNA-seq data**

1103 To infer transcriptional bursting kinetics, scRNA-seq UMI count matrices from the two wild-
1104 type samples (PCNA:eGFP and *w¹¹¹⁸*) were first subsetted per cluster. For the dorsal ectoderm,
1105 neuroectoderm (early) and mesoderm (early) clusters, maximum-likelihood kinetics inference
1106 was attempted for all detected genes according to the model implemented by Larsson, et al.⁶⁸.
1107 Additionally, pseudorandom bootstraps of the input data before maximum-likelihood inference
1108 in 100 iterations were performed. Through the bootstrapped inference, empirical confidence
1109 intervals could be derived. Next, we filtered away low-power inferences outside of the
1110 parameter space by sorting the values into two distributions based on a mixture of two normal
1111 distribution curves using the normalMixEM tool from the mixtools package in R (version 1.2.0)
1112 (<https://cran.r-project.org/web/packages/mixtools/vignettes/mixtools.pdf>) and the values in the
1113 higher distribution were kept. Genes with noisy confidence inferences (i.e. a broad confidence
1114 interval (CI)) were removed (For k_{on} : $\log_{10}(\text{CI } k_{on}) < 1.3 + 0.8 \log_{10}(k_{on})$ and for k_{bs} : $\log_{10}(\text{CI } k_{bs}) < 1.0 + 0.8 \log_{10}(k_{bs})$). Kinetics were obtained for 2232 genes in all three clusters and 1519
1115 genes in two of the three clusters. Genes where the CI for two clusters did not overlap were
1116 considered to be significantly different. Pearson correlations of the bursting kinetics for the DV
1117 clusters between the two wild-type samples were measured to control for reproducibility. DV
1118 genes were separated into kinetic classes based on whether they significantly changed in burst
1119 frequency ($n = 16$), burst size ($n = 25$), both burst size and burst frequency ($n = 6$) or did not
1120 change significantly ($n = 83$).

1121

1123 **Data and code availability**

1124 The datasets generated during this study are available at Gene Expression Omnibus with the
1125 Accession Number GEO: GSE211220.

1126

1127 **Acknowledgements**

1128 We thank Mounia Lagha, Christos Samakovlis, Akira Nakamura, John Lis, Renato Paro, Eric
1129 Wieschaus and Nicola Iovino for sharing reagents, Juanma Vaquerizas and Mounia Lagha for
1130 comments on the manuscript, the core facility for Bioinformatics and Expression Analysis
1131 (BEA) at Novum (supported by the board of research at the Karolinska Institute and the
1132 research committee at the Karolinska hospital) for help with sequencing, and NBIS/SciLifeLab
1133 for bioinformatics long-term support (WABI). Data handling was enabled by resources
1134 provided by the Swedish National Infrastructure for Computing (SNIC), partially funded by
1135 the Swedish Research Council through grant agreement no. 2018-05973. This work was
1136 supported by grants from the Swedish Research Council (Vetenskapsrådet) and the Swedish
1137 Cancer Society (Cancerfonden) to M.M.

1138

1139 **Author contributions**

1140 G.H. and R.V. performed experiments including PRO-seq, ATAC-seq, ChIP-seq as well as
1141 CUT&Tag with help from A.P. P-TEFb over-expression was performed by S.P. Bioinformatic
1142 analysis: J.R. with help from G.H. and R.V. Transcriptional kinetics: J.R., C.Z. and R.S.
1143 Conceptualization: M.M., R.V. and G.H. Writing: M.M. and G.H. with input from all authors.

1144

1145 **References**

- 1146 1. Hong, J.W., Hendrix, D.A., Papatsenko, D. & Levine, M.S. How the Dorsal gradient works:
1147 insights from postgenome technologies. *Proc Natl Acad Sci U S A* **105**, 20072-6 (2008).
- 1148 2. Reeves, G.T. & Stathopoulos, A. Graded dorsal and differential gene regulation in the
1149 Drosophila embryo. *Cold Spring Harb Perspect Biol* **1**, a000836 (2009).
- 1150 3. Roth, S., Stein, D. & Nusslein-Volhard, C. A gradient of nuclear localization of the dorsal
1151 protein determines dorsoventral pattern in the Drosophila embryo. *Cell* **59**, 1189-202 (1989).
- 1152 4. Rushlow, C.A., Han, K., Manley, J.L. & Levine, M. The graded distribution of the dorsal
1153 morphogen is initiated by selective nuclear transport in Drosophila. *Cell* **59**, 1165-77 (1989).
- 1154 5. Steward, R. Relocalization of the dorsal protein from the cytoplasm to the nucleus correlates
1155 with its function. *Cell* **59**, 1179-88 (1989).
- 1156 6. Rusch, J. & Levine, M. Threshold responses to the dorsal regulatory gradient and the
1157 subdivision of primary tissue territories in the Drosophila embryo. *Curr Opin Genet Dev* **6**,
1158 416-23 (1996).
- 1159 7. Ing-Simmons, E. *et al.* Independence of chromatin conformation and gene regulation during
1160 Drosophila dorsoventral patterning. *Nat Genet* **53**, 487-499 (2021).
- 1161 8. Espinola, S.M. *et al.* Cis-regulatory chromatin loops arise before TADs and gene activation,
1162 and are independent of cell fate during early Drosophila development. *Nat Genet* **53**, 477-486
1163 (2021).
- 1164 9. Core, L. & Adelman, K. Promoter-proximal pausing of RNA polymerase II: a nexus of gene
1165 regulation. *Genes Dev* **33**, 960-982 (2019).
- 1166 10. Gaertner, B. & Zeitlinger, J. RNA polymerase II pausing during development. *Development*
1167 **141**, 1179-83 (2014).
- 1168 11. Zeitlinger, J. *et al.* RNA polymerase stalling at developmental control genes in the Drosophila
1169 melanogaster embryo. *Nat Genet* **39**, 1512-6 (2007).
- 1170 12. Lagha, M. *et al.* Paused Pol II coordinates tissue morphogenesis in the Drosophila embryo.
1171 *Cell* **153**, 976-87 (2013).
- 1172 13. Koenecke, N., Johnston, J., He, Q., Meier, S. & Zeitlinger, J. Drosophila poised enhancers are
1173 generated during tissue patterning with the help of repression. *Genome Res* **27**, 64-74 (2017).
- 1174 14. Koenecke, N., Johnston, J., Gaertner, B., Natarajan, M. & Zeitlinger, J. Genome-wide
1175 identification of Drosophila dorso-ventral enhancers by differential histone acetylation
1176 analysis. *Genome Biol* **17**, 196 (2016).
- 1177 15. Boija, A. & Mannervik, M. Initiation of diverse epigenetic states during nuclear programming
1178 of the Drosophila body plan. *Proc Natl Acad Sci U S A* **113**, 8735-40 (2016).
- 1179 16. Holmqvist, P.H. *et al.* Preferential genome targeting of the CBP co-activator by Rel and Smad
1180 proteins in early Drosophila melanogaster embryos. *PLoS Genet* **8**, e1002769 (2012).

1181 17. Zeitlinger, J. *et al.* Whole-genome ChIP-chip analysis of Dorsal, Twist, and Snail suggests
1182 integration of diverse patterning processes in the Drosophila embryo. *Genes Dev* **21**, 385-90
1183 (2007).

1184 18. Kwak, H., Fuda, N.J., Core, L.J. & Lis, J.T. Precise maps of RNA polymerase reveal how
1185 promoters direct initiation and pausing. *Science* **339**, 950-3 (2013).

1186 19. Judd, J. *et al.* A rapid, sensitive, scalable method for Precision Run-On sequencing (PRO-
1187 seq). *bioRxiv*, 2020.05.18.102277 (2020).

1188 20. Stathopoulos, A., Van Drenth, M., Erives, A., Markstein, M. & Levine, M. Whole-genome
1189 analysis of dorsal-ventral patterning in the Drosophila embryo. *Cell* **111**, 687-701 (2002).

1190 21. Adelman, K. & Lis, J.T. Promoter-proximal pausing of RNA polymerase II: emerging roles in
1191 metazoans. *Nat Rev Genet* **13**, 720-31 (2012).

1192 22. Kwasnieski, J.C., Orr-Weaver, T.L. & Bartel, D.P. Early genome activation in Drosophila is
1193 extensive with an initial tendency for aborted transcripts and retained introns. *Genome Res* **29**,
1194 1188-1197 (2019).

1195 23. Chen, K. *et al.* A global change in RNA polymerase II pausing during the Drosophila
1196 midblastula transition. *Elife* **2**, e00861 (2013).

1197 24. Ramalingam, V., Natarajan, M., Johnston, J. & Zeitlinger, J. TATA and paused promoters
1198 active in differentiated tissues have distinct expression characteristics. *Mol Syst Biol* **17**,
1199 e9866 (2021).

1200 25. Hendrix, D.A., Hong, J.W., Zeitlinger, J., Rokhsar, D.S. & Levine, M.S. Promoter elements
1201 associated with RNA Pol II stalling in the Drosophila embryo. *Proc Natl Acad Sci U S A* **105**,
1202 7762-7 (2008).

1203 26. Sloutskin, A. *et al.* ElemeNT: a computational tool for detecting core promoter elements.
1204 *Transcription* **6**, 41-50 (2015).

1205 27. Haberle, V. & Stark, A. Eukaryotic core promoters and the functional basis of transcription
1206 initiation. *Nat Rev Mol Cell Biol* **19**, 621-637 (2018).

1207 28. Creyghton, M.P. *et al.* Histone H3K27ac separates active from poised enhancers and predicts
1208 developmental state. *Proc Natl Acad Sci U S A* **107**, 21931-6 (2010).

1209 29. Heintzman, N.D. *et al.* Histone modifications at human enhancers reflect global cell-type-
1210 specific gene expression. *Nature* **459**, 108-12 (2009).

1211 30. Rada-Iglesias, A. *et al.* A unique chromatin signature uncovers early developmental
1212 enhancers in humans. *Nature* **470**, 279-83 (2011).

1213 31. Visel, A. *et al.* ChIP-seq accurately predicts tissue-specific activity of enhancers. *Nature* **457**,
1214 854-8 (2009).

1215 32. Kvon, E.Z. *et al.* Genome-scale functional characterization of Drosophila developmental
1216 enhancers in vivo. *Nature* **512**, 91-5 (2014).

1217 33. Boija, A. *et al.* CBP Regulates Recruitment and Release of Promoter-Proximal RNA
1218 Polymerase II. *Mol Cell* **68**, 491-503 e5 (2017).

1219 34. Andersson, R. *et al.* An atlas of active enhancers across human cell types and tissues. *Nature*
1220 **507**, 455-461 (2014).

1221 35. Bose, D.A. *et al.* RNA Binding to CBP Stimulates Histone Acetylation and Transcription.
Cell **168**, 135-149 e22 (2017).

1223 36. Tippens, N.D. *et al.* Transcription imparts architecture, function and logic to enhancer units.
Nat Genet **52**, 1067-1075 (2020).

1225 37. Schaukowitch, K. *et al.* Enhancer RNA facilitates NELF release from immediate early genes.
Mol Cell **56**, 29-42 (2014).

1227 38. Mikhaylichenko, O. *et al.* The degree of enhancer or promoter activity is reflected by the
1228 levels and directionality of eRNA transcription. *Genes Dev* **32**, 42-57 (2018).

1229 39. Bailey, T.L. *et al.* MEME SUITE: tools for motif discovery and searching. *Nucleic Acids Res*
1230 **37**, W202-8 (2009).

1231 40. Castro-Mondragon, J.A. *et al.* JASPAR 2022: the 9th release of the open-access database of
1232 transcription factor binding profiles. *Nucleic Acids Res* **50**, D165-D173 (2022).

1233 41. He, Q., Johnston, J. & Zeitlinger, J. ChIP-nexus enables improved detection of in vivo
1234 transcription factor binding footprints. *Nat Biotechnol* **33**, 395-401 (2015).

1235 42. Hug, C.B., Grimaldi, A.G., Kruse, K. & Vaquerizas, J.M. Chromatin Architecture Emerges
1236 during Zygotic Genome Activation Independent of Transcription. *Cell* **169**, 216-228 e19
1237 (2017).

1238 43. Ghavi-Helm, Y. *et al.* Enhancer loops appear stable during development and are associated
1239 with paused polymerase. *Nature* **512**, 96-100 (2014).

1240 44. Ghavi-Helm, Y. *et al.* Highly rearranged chromosomes reveal uncoupling between genome
1241 topology and gene expression. *Nat Genet* **51**, 1272-1282 (2019).

1242 45. Batut, P.J. *et al.* Genome organization controls transcriptional dynamics during development.
Science **375**, 566-570 (2022).

1244 46. Price, D.H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.
Mol Cell Biol **20**, 2629-34 (2000).

1246 47. Gressel, S. *et al.* CDK9-dependent RNA polymerase II pausing controls transcription
1247 initiation. *Elife* **6**(2017).

1248 48. Jang, M.K. *et al.* The bromodomain protein Brd4 is a positive regulatory component of P-
1249 TEFb and stimulates RNA polymerase II-dependent transcription. *Mol Cell* **19**, 523-34
1250 (2005).

1251 49. Yang, Z. *et al.* Recruitment of P-TEFb for stimulation of transcriptional elongation by the
1252 bromodomain protein Brd4. *Mol Cell* **19**, 535-45 (2005).

1253 50. Zhou, Q., Li, T. & Price, D.H. RNA polymerase II elongation control. *Annu Rev Biochem* **81**,
1254 119-43 (2012).

1255 51. Dubnicoff, T. *et al.* Conversion of dorsal from an activator to a repressor by the global
1256 corepressor Groucho. *Genes Dev* **11**, 2952-7 (1997).

1257 52. Papagianni, A. *et al.* Capicua controls Toll/IL-1 signaling targets independently of RTK
1258 regulation. *Proc Natl Acad Sci U S A* **115**, 1807-1812 (2018).

1259 53. Nibu, Y., Zhang, H. & Levine, M. Interaction of short-range repressors with Drosophila CtBP
1260 in the embryo. *Science* **280**, 101-4 (1998).

1261 54. Qi, D., Bergman, M., Aihara, H., Nibu, Y. & Mannervik, M. Drosophila Ebi mediates Snail-
1262 dependent transcriptional repression through HDAC3-induced histone deacetylation. *EMBO J*
1263 **27**, 898-909 (2008).

1264 55. Rosenberg, M. *et al.* Motif-driven interactions between RNA and PRC2 are rheostats that
1265 regulate transcription elongation. *Nat Struct Mol Biol* **28**, 103-117 (2021).

1266 56. Dobrinic, P., Szczerba, A.T. & Klose, R.J. PRC1 drives Polycomb-mediated gene repression
1267 by controlling transcription initiation and burst frequency. *Nat Struct Mol Biol* **28**, 811-824
1268 (2021).

1269 57. Dellino, G.I. *et al.* Polycomb silencing blocks transcription initiation. *Mol Cell* **13**, 887-93
1270 (2004).

1271 58. Alecki, C. *et al.* RNA-DNA strand exchange by the Drosophila Polycomb complex PRC2.
1272 *Nat Commun* **11**, 1781 (2020).

1273 59. Bothma, J.P., Magliocco, J. & Levine, M. The snail repressor inhibits release, not elongation,
1274 of paused Pol II in the Drosophila embryo. *Curr Biol* **21**, 1571-7 (2011).

1275 60. Blythe, S.A. & Wieschaus, E.F. Establishment and maintenance of heritable chromatin
1276 structure during early Drosophila embryogenesis. *Elife* **5**(2016).

1277 61. Sun, Y. *et al.* Zelda overcomes the high intrinsic nucleosome barrier at enhancers during
1278 Drosophila zygotic genome activation. *Genome Res* **25**, 1703-14 (2015).

1279 62. Harrison, M.M., Li, X.Y., Kaplan, T., Botchan, M.R. & Eisen, M.B. Zelda binding in the
1280 early Drosophila melanogaster embryo marks regions subsequently activated at the maternal-
1281 to-zygotic transition. *PLoS Genet* **7**, e1002266 (2011).

1282 63. Koromila, T. *et al.* Odd-paired is a pioneer-like factor that coordinates with Zelda to control
1283 gene expression in embryos. *Elife* **9**(2020).

1284 64. Duan, J. *et al.* CLAMP and Zelda function together to promote Drosophila zygotic genome
1285 activation. *Elife* **10**(2021).

1286 65. Gaskill, M.M., Gibson, T.J., Larson, E.D. & Harrison, M.M. GAF is essential for zygotic
1287 genome activation and chromatin accessibility in the early Drosophila embryo. *Elife*
1288 **10**(2021).

1289 66. Li, X.Y., Harrison, M.M., Villalta, J.E., Kaplan, T. & Eisen, M.B. Establishment of regions of
1290 genomic activity during the Drosophila maternal to zygotic transition. *Elife* **3**(2014).

1291 67. Rodriguez, J. & Larson, D.R. Transcription in Living Cells: Molecular Mechanisms of
1292 Bursting. *Annu Rev Biochem* **89**, 189-212 (2020).

1293 68. Larsson, A.J.M. *et al.* Genomic encoding of transcriptional burst kinetics. *Nature* **565**, 251-
1294 254 (2019).

1295 69. Nicolas, D., Zoller, B., Suter, D.M. & Naef, F. Modulation of transcriptional burst frequency
1296 by histone acetylation. *Proc Natl Acad Sci U S A* **115**, 7153-7158 (2018).

1297 70. Zoller, B., Little, S.C. & Gregor, T. Diverse Spatial Expression Patterns Emerge from Unified
1298 Kinetics of Transcriptional Bursting. *Cell* **175**, 835-847 e25 (2018).

1299 71. Ortega, E. *et al.* Transcription factor dimerization activates the p300 acetyltransferase. *Nature*
1300 **562**, 538-544 (2018).

1301 72. Tie, F. *et al.* Polycomb inhibits histone acetylation by CBP by binding directly to its catalytic
1302 domain. *Proc Natl Acad Sci U S A* **113**, E744-53 (2016).

1303 73. Vaid, R., Wen, J. & Mannervik, M. Release of promoter-proximal paused Pol II in response
1304 to histone deacetylase inhibition. *Nucleic Acids Res* **48**, 4877-4890 (2020).

1305 74. Diamant, G. & Dikstein, R. Transcriptional control by NF-kappaB: elongation in focus.
1306 *Biochim Biophys Acta* **1829**, 937-45 (2013).

1307 75. Tantale, K. *et al.* Stochastic pausing at latent HIV-1 promoters generates transcriptional
1308 bursting. *Nat Commun* **12**, 4503 (2021).

1309 76. Pimmett, V.L. *et al.* Quantitative imaging of transcription in living Drosophila embryos
1310 reveals the impact of core promoter motifs on promoter state dynamics. *Nat Commun* **12**,
1311 4504 (2021).

1312 77. Falo-Sanjuan, J., Lammers, N.C., Garcia, H.G. & Bray, S.J. Enhancer Priming Enables Fast
1313 and Sustained Transcriptional Responses to Notch Signaling. *Dev Cell* **50**, 411-425 e8 (2019).

1314 78. Lee, C., Shin, H. & Kimble, J. Dynamics of Notch-Dependent Transcriptional Bursting in Its
1315 Native Context. *Dev Cell* **50**, 426-435 e4 (2019).

1316 79. Fukaya, T., Lim, B. & Levine, M. Enhancer Control of Transcriptional Bursting. *Cell* **166**,
1317 358-368 (2016).

1318 80. Fukaya, T. Dynamic regulation of anterior-posterior patterning genes in living Drosophila
1319 embryos. *Curr Biol* **31**, 2227-2236 e6 (2021).

1320 81. Hoppe, C. *et al.* Modulation of the Promoter Activation Rate Dictates the Transcriptional
1321 Response to Graded BMP Signaling Levels in the Drosophila Embryo. *Dev Cell* **54**, 727-741
1322 e7 (2020).

1323 82. Lammers, N.C. *et al.* Multimodal transcriptional control of pattern formation in embryonic
1324 development. *Proc Natl Acad Sci U S A* **117**, 836-847 (2020).

1325 83. Schulz, K.N. *et al.* Zelda is differentially required for chromatin accessibility, transcription
1326 factor binding, and gene expression in the early Drosophila embryo. *Genome Res* **25**, 1715-26
1327 (2015).

1328 84. Koch, R., Ledermann, R., Urwyler, O., Heller, M. & Suter, B. Systematic functional analysis
1329 of Bicaudal-D serine phosphorylation and intragenic suppression of a female sterile allele of
1330 BicD. *PLoS One* **4**, e4552 (2009).

1331 85. Jiang, J., Hoey, T. & Levine, M. Autoregulation of a segmentation gene in Drosophila:
1332 combinatorial interaction of the even-skipped homeo box protein with a distal enhancer
1333 element. *Genes Dev* **5**, 265-77 (1991).

1334 86. Tautz, D. & Pfeifle, C. A non-radioactive in situ hybridization method for the localization of
1335 specific RNAs in Drosophila embryos reveals translational control of the segmentation gene
1336 hunchback. *Chromosoma* **98**, 81-5 (1989).

1337 87. Tomancak, P. *et al.* Systematic determination of patterns of gene expression during
1338 Drosophila embryogenesis. *Genome Biol* **3**, RESEARCH0088 (2002).

1339 88. Tomancak, P. *et al.* Global analysis of patterns of gene expression during Drosophila
1340 embryogenesis. *Genome Biol* **8**, R145 (2007).

1341 89. Hammonds, A.S. *et al.* Spatial expression of transcription factors in Drosophila embryonic
1342 organ development. *Genome Biol* **14**, R140 (2013).

1343 90. Buenrostro, J.D., Giresi, P.G., Zaba, L.C., Chang, H.Y. & Greenleaf, W.J. Transposition of
1344 native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding
1345 proteins and nucleosome position. *Nat Methods* **10**, 1213-8 (2013).

1346 91. Blythe, S.A. & Wieschaus, E.F. Zygotic genome activation triggers the DNA replication
1347 checkpoint at the midblastula transition. *Cell* **160**, 1169-81 (2015).

1348 92. Hanyu-Nakamura, K., Sonobe-Nojima, H., Tanigawa, A., Lasko, P. & Nakamura, A.
1349 Drosophila Pgc protein inhibits P-TEFb recruitment to chromatin in primordial germ cells.
1350 *Nature* **451**, 730-3 (2008).

1351 93. Kockmann, T. *et al.* The BET protein FSH functionally interacts with ASH1 to orchestrate
1352 global gene activity in Drosophila. *Genome Biol* **14**, R18 (2013).

1353 94. Kaya-Okur, H.S. *et al.* CUT&Tag for efficient epigenomic profiling of small samples and
1354 single cells. *Nat Commun* **10**, 1930 (2019).

1355 95. Hainer, S.J. & Fazzio, T.G. High-Resolution Chromatin Profiling Using CUT&RUN. *Curr
1356 Protoc Mol Biol* **126**, e85 (2019).

1357 96. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**,
1358 357-9 (2012).

1359 97. Ramirez, F. *et al.* deepTools2: a next generation web server for deep-sequencing data
1360 analysis. *Nucleic Acids Res* **44**, W160-5 (2016).

1361 98. Liao, Y., Smyth, G.K. & Shi, W. featureCounts: an efficient general purpose program for
1362 assigning sequence reads to genomic features. *Bioinformatics* **30**, 923-30 (2014).

1363 99. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
1364 RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).

1365 100. Stathopoulos, A. & Levine, M. Whole-genome expression profiles identify gene batteries in
1366 *Drosophila*. *Dev Cell* **3**, 464-5 (2002).

1367 101. Saunders, A., Core, L.J., Sutcliffe, C., Lis, J.T. & Ashe, H.L. Extensive polymerase pausing
1368 during *Drosophila* axis patterning enables high-level and pliable transcription. *Genes Dev* **27**,
1369 1146-58 (2013).

1370 102. Feng, J., Liu, T., Qin, B., Zhang, Y. & Liu, X.S. Identifying ChIP-seq enrichment using
1371 MACS. *Nat Protoc* **7**, 1728-40 (2012).

1372 103. Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137 (2008).

1373 104. Quinlan, A.R. & Hall, I.M. BEDTools: a flexible suite of utilities for comparing genomic
1374 features. *Bioinformatics* **26**, 841-2 (2010).

1375 105. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587 e29
1376 (2021).

1377 106. Satija, R., Farrell, J.A., Gennert, D., Schier, A.F. & Regev, A. Spatial reconstruction of
1378 single-cell gene expression data. *Nat Biotechnol* **33**, 495-502 (2015).

1379

1380

1381 **Figure legends**

1382 **Figure 1. Promoter-proximal paused Pol II is established at DV regulated genes prior to**
1383 **ZGA but is released into elongation in a tissue-specific manner. a)** Schematic of embryonic
1384 DV patterning. From an initially transcriptionally inert naïve embryo (nuclear cycle (nc) 7-9,
1385 1-1.2 hours (h) after egg laying (AEL)), a dorsoventral (DV) nuclear gradient of the maternally
1386 supplied transcription factor dorsal (Dl) (nc 10-13, 1.5-2.5 h AEL) directs cell fate
1387 specifications at zygotic genome activation (ZGA) (nc 14, 2.5-3.5 h AEL). Distinct
1388 transcriptional programs initiated by the absence of Dl dorsally, moderate nuclear Dl laterally
1389 and high nuclear Dl ventrally lead to cell specification into dorsal ectoderm, neuroectoderm
1390 and mesoderm, respectively. Disrupted Dl gradient formation in *Toll* signaling mutants
1391 produces embryos composed entirely of presumptive dorsal ectoderm (*gd*⁷), neuroectoderm
1392 (*Toll*^{rm9/rm10}) and mesoderm (*Toll*^{10B}). **b)** Images of whole mount *in situ* hybridization in wild-
1393 type and *Toll* mutant embryos (2-4 h AEL) with probes hybridizing to mRNAs of representative
1394 DV regulated genes (*dpp*, *ind* and *twi*). **c)** Schematic of the experimental design to study spatio-
1395 temporal transcriptional dynamics during DV patterning. PRO-seq was performed on naïve
1396 wild-type embryos (nc 7-9, 60-80 min AEL) and *Toll* mutant embryos at ZGA (nc 14, 2.5-3 h
1397 AEL) and after gastrulation (> nc 14, 4.5-5 h AEL). **d)** Genome browser shots of stranded
1398 PRO-seq signal (RPKM x10³) at *dpp*, *ind* and *twi*. Promoters are shaded gray. **e)** Pausing index
1399 (PI) of DV and non-DV regulated genes from qPRO-seq in wild-type naïve (1 h) embryos and
1400 **(f)** PRO-seq in *Toll* mutants. **g)** PI of DV regulated genes partitioned by the tissue of expression
1401 from PRO-seq in *Toll* mutants. **h)** Metagene plots of *Toll* mutant PRO-seq (2.5-3 and 4.5-5 h)
1402 at DV regulated genes. Comparisons of the PI between DV and non-DV gene classes are from
1403 the Wilcoxon Rank-sum test.

1404 **Figure 2. Epigenomic profiling identifies chromatin states at DV enhancers and**
1405 **promoters that correlate with tissue-specific gene expression. a)** Schematic of the

1406 epigenomic profiling strategy for identifying tissue-specific DV enhancers genome-wide.
1407 PRO-seq identified DV genes were linked to regions within the same topologically associating
1408 domain (TAD) with differential chromatin accessibility (ATAC-seq), enrichment of the active
1409 histone mark H3K27ac and occupancy of CBP between *Toll* mutants. **b)** Boxplots of the fold
1410 change (\log_2) ATAC-seq, CBP and H3K27ac enrichment between *Toll* mutants at DV
1411 enhancers separated by the tissue of expression of their target genes. **c)** The correlation between
1412 the combined tissue-specific enhancer chromatin state score and target DV gene expression

1413 (PRO-seq gene body count (GBC)) for each tissue-specific gene classes. The *P*-value from
1414 Pearson's correlation is shown alongside the coefficient of determination (R^2). **d**) The fold
1415 change (\log_2) in enrichment between *Toll* mutants for the genomic datasets in **b** at promoters
1416 associated with DV enhancers. **e**) Correlations between the combined tissue-specific promoter
1417 chromatin state score and gene expression (PRO-seq, GBC). **f**) Genome browser shots of *Toll*
1418 mutant ATAC-seq (3 h, 4 h and 5 h AEL), H3K27ac and CBP ChIP-seq (2-4 h AEL) and PRO-
1419 seq (3 h) alongside D1 ChIP-nexus (2-4 AEL wild-type embryos)⁴¹ and zen (2-4 h AEL *gd*⁷
1420 embryos) and *twi* ChIP-seq^{13,14} at *dpp*, *ind* and *twi*. The genomic positions of DV enhancers
1421 and promoters are denoted. **g**) Genome browser closeups of *Toll* mutant H3K27ac and CBP
1422 signal at the *twi* promoter and enhancer. **h**) Boxplots showing the fold change (\log_2) in enhancer
1423 RNA (eRNA) activity measured from *Toll* mutant PRO-seq at DV and non-DV enhancers. **i**)
1424 Metagene profiles of *Toll* mutant Pol II (Rpb3) CUT&Tag (2-4 h AEL) and PRO-seq (3 h)
1425 signal (RPKM) at DV enhancers (\pm 5 kb of CBP) and promoters (\pm 5 kb of TSS). Comparisons
1426 of the enrichment at DV enhancer and promoter gene classes between *Toll* mutants are from
1427 the Wilcoxon signed-rank test.

1428

1429 **Figure 3. Tissue-specific P-TEFb recruitment is associated with the release of paused Pol**
1430 **II into productive elongation at DV promoters. a)** Schematic of P-TEFb (composed of CycT
1431 and CDK9 subunits) mediated release of promoter-proximal paused Pol II into productive
1432 elongation. P-TEFb phosphorylates serine 2 of the Pol II carboxyl-terminal domain (CTD) to
1433 stimulate elongation. BRD4/fs(1)h binds to acetylated histones and helps recruit P-TEFb to
1434 promoters. **b)** Boxplots showing the fold change (\log_2) in enrichment of CycT, Cdk9 and
1435 BRD4/fs(1)h from CUT&Tag in *Toll* mutant embryos at DV promoters and enhancers.
1436 Comparisons of the enrichment at DV enhancer and promoter gene classes between *Toll*
1437 mutants are from the Wilcoxon signed-rank test. **c)** Genome browser shots of *Toll* mutant CycT,
1438 Cdk9 and BRD4/fs(1)h CUT&Tag and H3K27ac ChIP-seq at *dpp*, *ind* and *twi*. **d)** Genome
1439 browser shot of *Toll* mutant PRO-seq, CBP ChIP-seq and CycT and BRD4/fs(1)h CUT&Tag
1440 at the *doc* locus. The position of the *doc* E1 enhancer deletion⁸ is denoted. **e)** ChIP-qPCR
1441 showing the enrichment of CycT and BRD4/fs(1)h at the promoters of *doc1*, *doc2* and *doc3* in
1442 *doc* enh del $^{\Delta\Delta}$ embryos (2-4 h AEL) relative to enh $^{+/+}$ embryos ($n = 3-4$). Relative occupancy
1443 is also shown at the intact *doc* enhancer (E4). Error bars show SEM. Significant differences in
1444 occupancy (two tailed, unpaired t-test) are indicated by asterisks (* = $P < 0.05$). **f)** RT-qPCR
1445 quantification of *CycT*, *Cdk9* and DV regulated genes (*dpp*, *zen*, *ind*, *sog*, *twi* and *sna*) mRNA
1446 levels (relative to 28S rRNA) in wild-type embryos and P-TEFb maternally overexpressed

1447 (OE) embryos. Error bars show SEM. Significant differences in mRNA (two tailed, unpaired
1448 t-test) are indicated by asterisks (* = $P < 0.05$, ** = $P < 0.01$, *** = $P < 0.001$). **g**) (top) Images
1449 of whole mount *in situ* hybridization in wild-type and P-TEFb OE mutant embryos (2-4 h AEL)
1450 with probes hybridizing to mRNAs of the DV regulated genes in **f** and (bottom) quantification
1451 of the proportion of embryos with normal or ectopic staining for each probe. The number of
1452 embryos sampled are detailed in the methods.

1453 **Figure 4. Repressors prevent the release of paused Pol II at DV promoters by excluding**
1454 **H3K27ac and recruiting Polycomb-mediated H3K27me3. a)** Schematic of the repressor
1455 activity domains and target genes of Dl and Sna-mediated repression. **b)** Metagene plots of *Toll*
1456 mutant H3K27ac ChIP-seq (2-4 h AEL) signal at DV regulated genes. **c-d)** Metagene plots of
1457 *Toll* mutant H3K27ac and H3K27me3 ChIP-seq at enhancers and gene bodies of Sna (**c**) and
1458 Dl (**d**) repressor targets. **e)** Metagene plots of *Toll* mutant H3K27me3 ChIP-seq signal at DV
1459 regulated genes. **f)** Genome browser shots of *Toll* mutant H3K27me3, H3K27ac and CBP
1460 ChIP-seq signal alongside Dl ChIP-nexus and Sna and P_c ChIP-seq from wild-type (2-4 h AEL)
1461 embryos at *dpp*, *ind* and *twi*.

1462 **Figure 5. DV regulated enhancers are temporally primed by increased chromatin**
1463 **accessibility and CBP-mediated histone acetylation prior to the commencement of DV**
1464 **transcription. a)** Schematic of the developmental stages profiled by ATAC-seq, ChIP-seq and
1465 CUT&Tag. The nuclear cycles (nc) and hours after egg laying (hAEL) are indicated. **b)**
1466 Boxplots of ATAC-seq enrichment (\log_2 TPM) at DV and non-DV enhancers and promoters,
1467 relative to shuffled genomic regions from wild-type embryos at nc 11, 12 and 13⁶⁰. **c)** Boxplots
1468 showing the \log_2 fold change (perturbation/control) in ATAC-seq signal at DV and shuffled
1469 enhancers and promoters after maternal RNAi depletion of Zld and opa⁶³, CLAMP⁶⁴ and
1470 zygotic GAF^{deGradFP}⁶⁵. *P*-values (Wilcoxon rank-sum test) show significant differences in
1471 accessibility compared to shuffled sites. **d)** Metagene plots of *Toll* mutant embryo (3 h, 4 h and
1472 5 h AEL) ATAC-seq signal (RPKM) at DV enhancers and promoters partitioned by the tissue
1473 of target gene activity. **e)** Proportion (%) of dorsal ectoderm, neuroectoderm and mesoderm
1474 enhancers that gained (\log_2 fold change (FC) ≥ 0.5), lost (\log_2 FC ≤ -0.5) or maintained stable
1475 chromatin accessibility (ATAC-seq) in 4 h and 5 h AEL embryos relative to 3 h. The
1476 accessibility was measured from *gd*⁷ at dorsal ectoderm enhancers, *Toll*^{rm9/rm10} at
1477 neuroectoderm enhancers and *Toll*^{10B} at mesoderm enhancers. **f)** Metagene plots of *Toll* mutant
1478 ATAC-seq signal (3 h, 4 h and 5 h AEL) at DV enhancers partitioned by the tissue of target

1479 gene activity and the change of accessibility (5 h relative to 3 h AEL). **g**) Boxplots of early
1480 (2.5-3 h) and late (4.5-5 h) *Toll* mutant PRO-seq gene body expression (\log_2 read count) of DV
1481 genes associated to enhancers with gained, lost or stable accessibility (5 h vs 3 h). Expression
1482 was measured for genes in the tissue mutant of activity. *P*-values (Wilcoxon rank-sum test)
1483 show significant differences in expression (2.5-3 h vs 4.5-5 h). **h**) Overlap (%) of DV and non-
1484 DV enhancers and promoters with ChIP-seq peaks (nc 8, 12, 14 (early and late)) called for the
1485 p300/CBP-mediated histone acetylation marks (H3K27ac, H3K18ac and H4K8ac) and the non-
1486 p300/CBP mark H3K9ac⁶⁶. **i-j**) Metagene plots of **(i)** CBP-catalyzed histone marks from nc 8
1487 ChIP-seq and **(j)** CBP CUT&Tag and ATAC-seq enrichment at DV enhancers acetylated or
1488 non-acetylated at nc 8. **k**) Boxplots of 2.5-3 h and 4.5-5 h (AEL) PRO-seq gene body read
1489 counts (\log_2) for DV genes linked to enhancers acetylated or not acetylated at nc 8. For each
1490 gene, the PRO-seq signal was taken from the *Toll* mutant of expression. *P*-values are from the
1491 Wilcoxon rank-sum test. **l**) Metagene plots of BRD4/fs(1)h and Cdk9 CUT&Tag signal from
1492 nc 7-9, 11-13 and 14 wild-type embryos at the promoters of DV genes linked to enhancers
1493 acetylated or non-acetylated at nc 8.

1494

1495 **Figure 6. Transcriptional kinetics inferred from scRNA-seq data show that DV genes**
1496 **have a high burst size and are regulated in burst size or frequency. a)** UMAP clustering of
1497 single-cell RNA-seq (scRNA-seq) from DV relevant clusters in wild-type and *Toll* mutant 2.5-
1498 3.5h embryos⁷ based on the expression of DV genes identified by PRO-seq. **b)** Schematic of
1499 the two-state transcriptional model used for transcriptome-wide inference of burst kinetics from
1500 scRNA-seq⁶⁸. **c)** Boxplots showing the burst size and frequency (\log_2) of DV genes classified
1501 by the tissue of expression in DV relevant UMAP clusters from wild-type scRNA-seq. **d)**
1502 Boxplots of the burst size and frequency of genes classified by the presence of *de novo*
1503 identified promoter motifs and compared to all DV genes. **e)** Correlations between
1504 transcriptional kinetics and PRO-seq promoter read counts (\log_2). The mRNA level (\log_2 TPM)
1505 of genes is denoted. **f)** Plots showing the transcriptional kinetics of individual DV genes (*dpp*,
1506 *CG45263*, *SoxN*, *Meltrin*, *twi* and *sna*) across DV relevant UMAP clusters. Error bars show the
1507 95% confidence intervals. Genes with statistically significant increases in bursting kinetics in
1508 the cluster of expression relative to the OFF clusters are denoted. **g)** Heatmap showing the
1509 coefficient of determination (R^2) between the enrichment of various genomic datasets at DV
1510 enhancers and promoters compared to burst frequency (BF) or size (BS). Comparisons with
1511 significant positive and negative correlations are denoted by boxes. **h)** Distribution of DV
1512 enhancer density in respect of genomic distance from the TSS of target genes with inferred

1513 kinetics (\log_{10} bp). Enhancers with a distance \leq 700 bp from the TSS were classified as
1514 proximal ($n = 22$) and above this threshold defined as distal ($n = 115$). **i)** Boxplots showing the
1515 fold change (\log_2) in transcriptional kinetics between the ON tissue and mean of the OFF
1516 tissues for genes regulated by proximal and distal enhancers. **j)** Schematic model of DV gene
1517 activation.

1518

1519

1520 **Figure S1. PRO-seq identifies DV regulated genes with promoter-proximal paused Pol II**
1521 **that persists across tissue types and developmental stages.** **a)** Fold change (\log_2 TPM +1)
1522 of PRO-seq gene body read counts (GBC) (defined as the coding region of genes) in *Toll*
1523 mutants for DV genes grouped by the tissue of expression and non-DV genes. P-values
1524 denoting significant differences for DV gene groups between *Toll* mutants are from the
1525 Wilcoxon signed-rank test. **b)** Counts for the differentially expressed genes identified by PRO-
1526 seq, grouped by the tissue of expression. **c)** The overlap (%) PRO-seq identified DV regulated
1527 genes with DV genes previously identified by whole genome microarray²⁰. **d)** Images of whole
1528 mount *in situ* hybridization in wild-type embryos (2-4 h AEL) with probes for mRNAs of
1529 representative DV regulated genes identified by PRO-seq. Images of *zen*, *ush*, *SoxN*, *Meltrin*,
1530 *twi*, *sna* and *htl* were obtained from the BDGP database⁸⁷⁻⁸⁹. **e)** Genome browser shots of
1531 stranded PRO-seq signal (RPKM x10³) at *Wnt2*, *wnd* and *meso18E*. Promoters are shaded gray.
1532 **f)** Pausing index (PI) of DV regulated genes compared to anterior-posterior (AP)¹⁰¹ and non-
1533 DV genes in *Toll* mutant PRO-seq. **g)** Comparisons of the transcription level (GBC (\log_2
1534 TPM+1)) of zygotic genes expressed at different embryonic developmental stages²² and DV
1535 genes between naïve wild-type embryos in qPRO- and PRO-seq. **h)** Metagene plots of naïve
1536 qPRO- and PRO-seq signal at developmentally staged and DV genes. **i)** Genome browser shots
1537 of stranded qPRO- and PRO-seq signal (RPKM x10³) from naïve wild-type embryos at
1538 representative nc 7-9 expressed genes. **j)** Comparisons of the PI of the gene classes from **g**
1539 between naïve wild-type embryos in qPRO- and PRO-seq. **k)** Representation (%) of core
1540 promoter elements from the CORE database²⁶ at the promoters of DV regulated ($n = 195$) and
1541 all ($n = 13,965$) genes. **l)** Venn diagrams of the overlap of DV regulated genes with Inr, DPE
1542 and Bridge motif. **m)** Representation (%) and odds ratio (\log_2) for *de novo* identified motifs at
1543 the promoters of DV, AP and other genes. **n)** *De novo* identified motif densities for Inr, Inr-
1544 DPE, Mad-Brk, GAGA and TATA at the promoters (from 100 bp downstream to 50 bp
1545 upstream of the TSS) of DV, AP and other genes. **o)** Metagene plots of *Toll* mutant CUT&Tag
1546 (2-4 h AEL) at DV regulated genes performed with antibodies against Pol II (Rpb3) and serine
1547 5 phosphorylated (5SerP) Pol II. **p)** PRO-seq promoter counts (PC) (\log_2 TPM+1), GBC and
1548 PI for representative DV genes from 2.5-3 h and 4.5-5 h AEL *Toll* mutants.

1549
1550 **Figure S2. Characterization of tissue-specific DV enhancers identified by epigenomic**
1551 **profiling of chromatin state.** **a)** Counts for the tissue-specific DV enhancers and **(b)**
1552 corresponding promoters identified partitioned by the tissue of activity of target genes. **c)**
1553 Enhancer-linked DV genes binned by the number of paired enhancers. **d)** Distribution of DV

1554 enhancer density in relation to genomic distance from the TSS of target genes. Enhancers with
1555 a distance \leq 700 bp from the TSS were classified as proximal and above this threshold defined
1556 as distal. **e**) Metagene profiles of CBP, ATAC-seq and H3K27ac enrichment at DV enhancers
1557 (\pm 5 kb of CBP peak). **f**) Violin plots of the genomic length distributions (kb) of peaks called
1558 for CBP, ATAC-seq and H3K27ac overlapping DV enhancers. **g**) Enriched annotations
1559 associated with the enhancer reporter activities of non-coding genomic fragments (Vienna
1560 Tiles, VT) that overlap DV enhancers partitioned by the tissue of activity³². **h**) Images of
1561 whole-mount *in situ* hybridization of LacZ reporter activity driven by representative VT
1562 enhancer fragments that overlap identified DV enhancers. **i**) Metagene profiles and heatmaps
1563 (\pm 5 kb of CBP peak) of *Toll* mutant H3K27ac and CBP ChIP-seq signal (RPKM) at dorsal
1564 ectoderm, neuroectoderm and mesoderm enhancers. **j**) Receiver operating characteristic (ROC)
1565 curves for ATAC-seq, CBP and H3K27ac individually and combined at DV enhancers and
1566 promoters. **k**) Metagene profiles and heatmaps (\pm 5 kb of TSS) of *Toll* mutant CBP and ATAC-
1567 seq signal (RPKM). **l**) Genome browser closeups of *Toll* mutant PRO-seq (3 h AEL) signal at
1568 the *twi* promoter and enhancer.

1569

1570 **Figure S3. Detection of tissue-specific transcription factors at DV enhancers and**
1571 **examination of genome organization. a)** Significantly enriched motifs from the JASPAR
1572 Insects CORE redundant TF motif database at DV enhancers, separated by the tissue of activity.
1573 **b)** Cumulative enrichment scores of the motifs from **a** at DV enhancers. **c)** Overlap (%) of
1574 peaks called for Dl, zen, Mad and *twi* with all DV enhancers and enhancers partitioned by the
1575 tissue of target gene activity. **d)** Normalized Hi-C contact probabilities (5-kb resolution) for
1576 representative DV regulated genes (*dpp*, *ind* and *twi*) in *Toll* mutant (2-3 h AEL) embryos from
1577 Ing-Simmons, et al. ⁷.

1578

1579 **Figure S4. Tissue-specific P-TEFb and BRD4/fs(1)h recruitment to DV genes. a)** Metagene
1580 profiles and heatmaps (\pm 5 kb of TSS) of *Toll* mutant CUT&Tag (2-4 h AEL) at DV regulated
1581 genes with antibodies against the P-TEFb subunits CycT and Cdk9 and the co-activator
1582 BRD4/fs(1)h. **b)** ChIP-qPCR validation of tissue-specific enrichment of CycT at DV regulated
1583 gene promoters (*dpp*, *tld*, *sog*, *ths*, *ind*, *sna* and *twi*) in *Toll* mutants. Enrichment is measured
1584 at DV targets relative to the signal at representative intergenic regions. Error bars show SEM.
1585 Significant differences in enrichment at promoters between the mutant that expresses the gene
1586 versus the mutants that do not (two tailed, unpaired t-test) are indicated by asterisks (* = $P <$
1587 0.05, ** = $P < 0.01$, *** = $P < 0.001$). **c)** Metagene profiles and heatmaps (\pm 5 kb of CBP peak)

1588 of *Toll* mutant CycT, Cdk9 and BRD4/fs(1)h CUT&Tag signal (RPKM) at dorsal ectoderm,
1589 neuroectoderm and mesoderm enhancers. **d)** RT-qPCR quantification of *doc1*, *doc2*, *doc3* and
1590 *Elba3* mRNA levels (relative to *RpL32*) from doc enhancer (enh) del^{Δ/Δ} embryos (2-4 h AEL)
1591 and *PCNA-eGFP* and enh^{+/+} embryos ($n = 3$). **e)** ChIP-qPCR showing the enrichment of
1592 H3K27ac, H3K27me3 and CBP at the promoters of *doc1*, *doc2* and *doc3* in doc enh del^{Δ/Δ}
1593 embryos (2-4 h AEL) relative to enh^{+/+} embryos ($n = 3-4$). Relative occupancy is also shown
1594 at an intact doc enhancer (E4). Error bars show SEM. Significant differences in occupancy
1595 (two tailed, unpaired t-test) are indicated by asterisks (* = $P < 0.05$). **f)** ChIP-qPCR showing
1596 the % input precipitated by anti-CycT at the promoters and enhancers of DV regulated genes
1597 (*dpp*, *ind* and *twi*) and an intergenic control region in chromatin from wild-type and P-TEFb
1598 maternally overexpressed (OE) embryos (2-4 h AEL). Error bars show SEM. Significant
1599 differences in the % input precipitated at targets between wild-type and P-TEFb OE embryos
1600 (two tailed, unpaired t-test) are indicated by asterisks (* = $P < 0.05$). **g)** Odds ratios measuring
1601 the strength of association between *in situ* ectopic expression observed in P-TEFb OE, relative
1602 to wild-type embryos, for DV regulated genes. **h)** Correlation between *in situ* ectopic
1603 expression of DV genes in P-TEFb OE embryos (odds ratio P-TEFb OE/wild-type) and the
1604 relative CUT&Tag promoter occupancy of CycT at the same DV genes in inactive Toll mutant
1605 embryos relative to active. *P*-values are from Fisher's exact test.

1606

1607 **Figure S5. Repressors occupy DV enhancers and promoters in a tissue-specific manner.**
1608 **a)** Overlap (%) of DV enhancers and promoters, partitioned by the tissue of target gene activity,
1609 with peaks called from ChIP-seq for Sna^{14 13} and ChIP-nexus for Dl⁴¹. **b)** Metagene profiles
1610 (± 5 kb of CBP peak) of *Toll* mutant (2-4 h AEL) Dl CUT&Tag signal (RPKM) at Sna repressed
1611 enhancers ($n = 13$). **c)** Metagene profiles (± 5 kb of CBP peak) of *Toll* mutant (3 h AEL) ATAC-
1612 seq signal (RPKM) at Sna repressed enhancers ($n = 13$). **d)** Metagene profiles (± 5 kb of CBP
1613 peak) of Dl ChIP-nexus and Sna and Pc (PRC1) ChIP-seq signal (RPKM) at DV enhancers and
1614 promoters. **e)** Metagene profiles comparing Pc ChIP-seq signal at DV enhancers and promoters
1615 partitioned by the tissue of target gene activity. **f)** Overlap (%) of DV enhancers and promoters
1616 with known Polycomb Response Elements (PREs)⁵⁸.

1617

1618 **Figure S6. Temporal dynamics of DV enhancer and promoter chromatin states. a)**
1619 Overlap (%) of DV and non-DV enhancers and promoters with Zld ChIP-seq peaks from nc 8,
1620 13 and 14 wild-type embryos⁶². For measuring overlaps, promoter regions were defined as
1621 (TSS ± 750 bp). **b)** (Top) Metagene plots and (bottom) heatmaps of Zelda (Zld) ChIP-seq

1622 enrichment in nc 8, 13 and 14 wild-type embryos at DV enhancers and promoters ⁶². **c)**
1623 Metagene plots of ChIP-seq enrichment for the pioneer factors Zld ⁶¹, opa ⁶³, CLAMP ⁶⁴ and
1624 GAF ^{13,14} from wild-type embryos at DV enhancers (\pm 5 kb of CBP peak) and promoters (\pm 5
1625 kb of TSS). **d)** Images of whole-mount *in situ* hybridization with a probe against *schnurri* (*shn*)
1626 mRNA in wild-type and *Toll* mutant embryos (2-4 h AEL). **e)** Genome browser shot of ATAC-
1627 seq signal from wild-type naïve embryos (nc 11, 12 and 13) ⁶⁰ and *Toll* mutant embryos (3 h,
1628 4 h and 5 h AEL) alongside Zld, GAF, opa and CLAMP ChIP-seq and *Toll* mutant PRO-seq
1629 (3 h AEL) at the *shn* locus. The major *shn* promoter active during early embryogenesis and
1630 associated enhancers are denoted. **f)** (Top) Images of whole-mount *in situ* hybridization of
1631 LacZ reporter activity driven by VT enhancer fragments that overlap *shn* enhancers with
1632 predicted early (E1) and late (E2) embryonic activity, alongside *in situ* hybridization with a
1633 probe against endogenous *shn* mRNA in wild-type embryos at corresponding developmental
1634 stages. (Bottom) Plots of the mean ATAC-seq signal (log₂ read count) at the E1 and E2
1635 enhancers (3 h, 4 h and 5 h AEL) in the *gd*⁷ mutant compared to *Toll*^{rm9/rm10} and *Toll*^{10B} ($n = 3$).
1636 Error bars show SEM. Significant differences in the accessibility between *gd*⁷ and
1637 *Toll*^{rm9/rm10}/*Toll*^{10B} (two tailed, unpaired t-test) are indicated by asterisks (* = $P < 0.05$, ** = P
1638 < 0.01, *** = $P < 0.001$). **g)** Metagene plots of the ChIP-seq enrichment of histone marks
1639 (H3K27ac, H3K18ac, H4K8ac, H3K9ac, H3K4me1 and H3K4me3) ⁶⁶ at DV, non-DV and
1640 shuffled enhancers and promoters from wild-type embryos at nc 8, 12 and 14 (early and late).
1641 **h)** Venn diagrams of the overlap between DV enhancers bound by H3K27ac, H3K18ac and
1642 H4K8ac across the time course. **i)** Overlap of DV enhancers acetylated or non-acetylated
1643 already at nc 8 with nc 8 Zld ChIP-seq peaks. **j)** Boxplots of CUT&Tag enrichment (log₂ TPM)
1644 of CBP, Cdk9 and BRD4/fs(1)h at DV and non-DV enhancers and promoters relative to
1645 shuffled genomic control regions from wild-type embryos at nc 7-9, 11-13 and 14. P-values
1646 (Wilcoxon rank-sum test) show significant enrichment compared to shuffled regions. **k-l)**
1647 Metagene plots of **(k)** CBP-catalyzed histone marks from nc 8 ChIP-seq and **(l)** CBP CUT&Tag
1648 and ATAC-seq enrichment at the promoters of DV genes linked to early acetylated or non-
1649 acetylated enhancers at nc 8.

1650

1651 **Figure S7. Identification of DV relevant cell clusters from scRNA-seq data based on PRO-**
1652 **seq identified DV genes. a)** UMAP clustering of single-cell RNA-seq (scRNA-seq) data from
1653 wild-type embryos (2.5-3.5 h AEL) ⁷. DV-relevant clusters are shown in bold, **b)** Projections
1654 of the mean expression (z-score) of dorsal ectoderm, neuroectoderm and mesoderm genes
1655 identified by PRO-seq on the UMAP of wild-type cells from DV relevant clusters from **a**

1656 reclustered according to the expression of PRO-seq DV genes (see methods). **c)** Projections of
1657 the expression of the marker DV used to identify the 6 clusters from the UMAP from wild-type
1658 cells in **b** and violin plots of the expression (\log_2 TPM) for each gene in the assigned cell
1659 clusters (see Fig. 6a). **d)** The assignment (%) of DV relevant cells from wild-type and *Toll*
1660 mutant embryo scRNA-seq UMAP clusters (see Fig. 6a). **e)** Projections of *dpp*, *ind* and *twi*
1661 expression on UMAPs from *Toll* mutant scRNA-seq (see Fig. 6a).

1662


1663 **Figure S8. Transcriptome-wide inference of burst kinetics from single-cell expression**
1664 **data.** **a)** Correlation plots of burst size (\log_2) and burst frequency (\log_2) kinetics inferred for all
1665 genes in DV relevant (dorsal ectoderm, neuroectoderm (early) and mesoderm (early)) scRNA-
1666 seq clusters between *PCNA-eGFP* and *w¹¹¹⁸* control (wild-type) lines. R^2 and *P*-values relating
1667 to the correlations are shown. **b)** Boxplots of the burst size (\log_2) and burst frequency (\log_2) for
1668 DV and AP regulated genes, alongside genes partitioned by the stage of expression during early
1669 embryogenesis. **c)** Correlation plots of burst kinetics and the PRO-seq promoter read count
1670 (\log_2) for DV regulated genes. **d)** Venn diagram showing the overlap between differentially
1671 expressed DV genes identified from *Toll* mutant PRO-seq ($n = 195$), the DV genes paired with
1672 enhancers ($n = 105$) and DV genes with a significant change in either one or both inferred
1673 transcriptional kinetic between DV relevant clusters from the wild-type embryo scRNA-seq
1674 data ($n = 47$). **e)** The number of DV genes with a significant kinetic change between DV-
1675 relevant clusters and the proportion (%) that change in burst size and frequency for the genes
1676 partitioned according to the tissue of expression. **f)** Heatmaps showing the expression level (z-
1677 score) of DV genes with a significant change in at least one kinetic parameter across profiled
1678 in single cells assigned to DV-relevant clusters, partitioned by the tissue of expression. Whether
1679 each DV gene changes significantly in burst size (BS) and/or burst frequency (BF) and has
1680 been paired to one or more enhancers is denoted. For each gene, the mean BF, BS, k_{on} , k_{off} and
1681 k_{syn} kinetic values from DV-relevant clusters are plotted. **g)** Correlation plots of the fold change
1682 in burst kinetics (\log_2 active tissue/inactive tissues) and DV enhancer and promoter tissue-
1683 specific chromatin state scores. **h)** Boxplots showing the inferred transcriptional parameters for
1684 DV genes in the active tissue and inactive tissues. DV genes are partitioned into kinetic classes
1685 based on whether they have significant changes in burst frequency, burst size or both between
1686 the active and inactive tissues (see Fig. S8h). *P*-values (Wilcoxon rank-sum test) show
1687 significant differences in each parameter for the kinetic classes between the active and inactive
1688 tissues. **i)** Boxplots of the \log_2 fold change (active tissue/inactive tissues) in each parameter for
1689 the kinetic classes. *P*-values (Wilcoxon rank-sum test) show significant differences the fold

1690 change between different kinetic classes. **j)** Heatmap (from 0 to 1) showing the coefficient of
1691 determination (R^2) for DV enhancer and promoter tissue-specific chromatin state compared to
1692 kinetic parameter scores. DV genes were classified according to whether they showed a
1693 significant change in BS, BF or both between their tissue of activity and inactive tissues.
1694 Comparisons with significant positive and negative correlations are denoted by boxes.


Figure 1

a


Embryonic dorsoventral (DV) patterning



b



c



d







Figure 2


a




b




c




d




e




f



g



h



i






Figure 3


a




b




c




d



e



f



g




Figure 4






Figure 5


a




b



c




d




e DV enhancer accessibility (vs 3 h)


Legend: Gained (\log_2 FC ≥ 0.5), Stable, Lost (\log_2 FC ≤ -0.5)




f




g




h




i



k



j



l




Figure 6

